Tag Archives: Biotechnology

Zeteo Biomedical Expands into Pulmonary Drug Delivery with AriesMR Active Dry Powder Inhaler

New ZTECH-P™ pulmonary platform provides active, propellant-free powder aerosolization without reliance on patient inspiratory effort and supports single- and dual-API combination products

AUSTIN, Texas, Sept. 15, 2026 (SEND2PRESS NEWSWIRE) — Zeteo Biomedical LLC today announced the expansion of its ZTECH-P™ powder drug-delivery platform into pulmonary delivery with the introduction of AriesMR™, a reloadable active dry powder inhaler designed for controlled pulmonary administration of pharmaceutical powders without reliance on patient-generated inspiratory energy for powder aerosolization or the use of CFC/HFA propellants.

Image caption: AriesMR™ Active Dry Powder Inhaler.

Unlike conventional passive dry powder inhalers that depend substantially on a patient’s inspiratory effort to disperse and aerosolize a formulation, AriesMR uses an integrated mechanical energy source to actively aerosolize and deliver the powder. The orientation-independent platform provides configurable dose and aerosolization parameters that can be optimized with formulation and particle characteristics for pulmonary delivery.

“AriesMR extends technologies we have developed and refined for nasal powder delivery into a pulmonary platform designed around many of the same challenges our pharmaceutical partners face—dose control, formulation protection, combination-product development and scalable manufacturing,” said Timothy Sullivan, Founder and Chief Executive Officer of Zeteo Biomedical.

“Importantly, the technology provides active powder aerosolization without requiring either HFA propellants or the patient’s inspiratory effort as the primary energy source for powder dispersion.”

The platform provides pharmaceutical developers with another approach to pulmonary combination-product development at a time when the industry is evaluating new inhalation technologies, including propellant-free alternatives to conventional pressurized inhaler platforms.

AriesMR incorporates replaceable unit-dose powder cartridges in a compact, mechanically actuated device, with on-board storage for up to six cartridges and a removable and replaceable mouthpiece. The device requires no battery power and is designed to operate independently of device orientation.

The platform can support single-API and dual-API configurations, including architectures in which separate powder formulations are maintained within the primary packaging until the point of delivery. This capability may enable combination-product strategies where formulation compatibility, stability or other development considerations make conventional co-formulation difficult.

AriesMR is being developed as part of Zeteo’s integrated combination-product development platform, bringing together delivery-device engineering, formulation and particle optimization, unit-dose primary packaging, product characterization and manufacturing technology. The platform is designed to support programs from early feasibility and preclinical development through clinical translation and commercial scale-up.

The expansion into pulmonary delivery builds on Zeteo’s existing ZTECH-P™ and ZTECH-L™ platforms supporting nasal, nose-to-brain, ophthalmic, sublingual and other non-invasive routes of administration.

Sullivan will participate in the IPAC-RS 2026 Nasal Innovation Forum, September 16–17 in Jersey City, New Jersey, where Zeteo will present work involving its intranasal powder delivery technology and meet with pharmaceutical and drug-delivery developers.

“Many of the formulation, device, primary-container and manufacturing challenges encountered in nasal powder development have direct parallels in pulmonary combination-product development,” Sullivan added. “The Forum provides an opportunity to discuss how those capabilities can be applied across both routes and to explore pulmonary programs where an active, propellant-free powder delivery approach may offer advantages.”

Learn more: https://zeteobiomed.com/pulmonary-drug-delivery/

ABOUT ZETEO BIOMEDICAL

Zeteo Biomedical LLC is a Cedar Park, Texas-based drug delivery technology and combination-product development company. Zeteo develops configurable delivery platforms for powder and liquid formulations across nasal, pulmonary, ophthalmic, sublingual and other non-invasive routes of administration. The company’s capabilities integrate delivery-device engineering, primary packaging, formulation and product development, in vitro characterization, manufacturing technology and commercialization support. For more information, visit Zeteo Biomedical to learn more about the AriesMR™ active dry powder inhaler: https://zeteobiomed.com/

Media Contact: Cathy Diehl, zeteo@zeteobiomed.com

MULTIMEDIA

Image link for media: https://www.Send2Press.com/300dpi/26-0915-s2p-ariesmr-300dpi.webp

Image caption: AriesMR™ Active Dry Powder Inhaler

LOGO: https://zeteobiomed.com/wp-content/uploads/2026/09/ZeteoLogo-transparent.png

NEWS SOURCE: Zeteo Biomedical LLC

This press release was issued on behalf of the news source (Zeteo Biomedical LLC), who is solely responsible for its accuracy, by Send2Press Newswire. Image, if any, was provided by the news source and not this website or the wire service. Information is believed accurate, as provided by the news source, but is not guaranteed.

To view the original story, visit: https://www.send2press.com/wire/zeteo-biomedical-expands-into-pulmonary-drug-delivery-with-ariesmr-active-dry-powder-inhaler/

NeuroDex ExoSORT Platform Demonstrates Treatment-Responsive Blood-Based Measurement of Neuronal TDP-43 in People Living with ALS

NeuroDex's neuron-derived extracellular vesicle (NDE) technology measured neuron-specific TDP-43 in blood samples

NATICK, Mass., July 1, 2026 (SEND2PRESS NEWSWIRE) — NeuroDex, a precision diagnostics company specializing in the isolation and analysis of neuron-derived extracellular vesicles (NDEs) from blood, today announced new findings supporting NDE-associated TDP-43 as a treatment-responsive biomarker in amyotrophic lateral sclerosis (ALS).

Image caption: NeuroDex Inc.

TDP-43 mislocalization and aggregation occur in more than 97% of ALS cases, about 40% of frontotemporal dementia and a substantial proportion of Alzheimer’s-spectrum disease, either as co-pathology or primary pathology (Limbic-predominant Age-related TDP-43 Encephalopathy,LATE). Despite its central role across neurodegenerative diseases, reliable biofluid biomarkers capable of measuring TDP-43 pathology in living patients have been elusive.

Conventional plasma TDP-43 measurements are limited by substantial biological background, as TDP-43 is expressed throughout the body and detected from numerous peripheral cell types. NeuroDex’s proprietary ExoSORT™ platform addresses this challenge by selectively enriching neuron-derived extracellular vesicles from blood, providing a minimally invasive window into molecular processes occurring within neurons of the brain and spinal cord.

Across multiple independent cohorts, ExoSORT-based analysis demonstrated that NDE-associated TDP-43 distinguished sporadic ALS from healthy controls. These findings were reproduced across three cohorts: 75 sporadic ALS versus healthy controls (44% increase, P=0.0003); 25 sporadic ALS versus 30 healthy controls (52% increase, P=0.002); and a third cohort of 52 ALS versus 37 healthy controls, in which NDE-associated TDP-43 was markedly elevated in disease (more than twofold higher; P<0.0001).

Longitudinal analyses further showed that NDE-associated TDP-43 increases over time as disease progresses. In the most recent cohort, NDE-associated TDP-43 rose over time in sporadic ALS and tracked clinical status. Within-patient longitudinal modeling estimated an increase of approximately 45% per year in sporadic ALS, and TDP-43 levels were associated with disease severity as measured by the ALSFRS-R.

“TDP-43 is emerging as a central pathology in neurodegeneration, yet measuring it in biofluids has been a long-standing challenge. A blood-based readout of TDP-43 could enable better patient selection and treatment monitoring and make clinical trials more efficient. These data are encouraging and support moving into clinical validation,” said Dr. Ajay Verma, CEO of Twilight, which works with NeuroDex to develop TDP43 biomarkers for ALS and FTD.

TDP43 can also serve as a treatment response biomarker. In a recent phase 2b randomized, placebo- controlled clinical trial (PARADIGM) conducted by NeuroSense Therapeutics (Nasdaq: NRSN) with its lead product candidate PrimeC (Cudkowicz et al. 2026), NeuroDex applied its ExoSORT workflow to serial samples collected longitudinally from study participants across all scheduled study visits. NDE-associated TDP-43 was measured in serial blood samples obtained throughout the trial, enabling assessment of biomarker trajectories over time in both placebo-treated and actively treated participants.

In this trial, NDE-associated TDP-43 increased over time in the placebo group, consistent with the natural-history pattern observed in NeuroDex’s prior studies. In contrast, participants receiving PrimeC demonstrated a statistically significant reduction in NDE-associated TDP-43 from baseline over the 6-month treatment period.

Notably, the biomarker analyses were derived from the same randomized clinical dataset that demonstrated favorable effects on functional decline, survival, and additional disease-relevant biomarkers. Taken together with NeuroDex’s prior work, these findings strengthen the evidence linking NDE-associated TDP-43 to ALS disease biology and support its continued evaluation in clinical studies as a pharmacodynamic biomarker.

The analysis was performed using NeuroDex’s ExoSORT platform, the first automated and scalable technology designed specifically for enrichment of neuron-derived extracellular vesicles from blood samples “In our Phase 2b PARADIGM clinical trial, PrimeC demonstrated a meaningful slowing of disease progression and an improvement in survival. The opportunity to pair that clinical effect with a blood-based measure of TDP-43 pathology is an important step toward understanding treatment effects on the underlying biology,” said Alon Ben-Noon, Chief Executive Officer of NeuroSense Therapeutics.

Dr. Erez Eitan, NeuroDex CEO added “We are excited to see NDE-associated TDP-43 distinguish disease from healthy controls and change over time in ALSThese results demonstrate the power of our NDE technology to take pathological proteins with broad tissue expression and transform them into neuron-specific biomarkers.”

ABOUT EXOSORT™ AND NEURON-DERIVED EVS

ExoSORT™ is NeuroDex’s proprietary automated platform for the enrichment of neuron-derived extracellular vesicles (NDEs) from blood samples. Using a combination of highly specific neuronal antibodies and a scalable 96-well workflow, ExoSORT™ selectively isolates extracellular vesicles originating from the brain, increasing the neuronal signal by more than 50-fold compared with conventional plasma analyses. By enriching for brain-derived vesicles, ExoSORT™ enables detection of disease-associated proteins that are also present in other tissues, such as TDP-43.

ABOUT NEURODEX

NeuroDex is a precision diagnostics company focused on unlocking the central nervous system through the analysis of neuron-derived extracellular vesicles isolated from blood. Its proprietary ExoSORT™ platform enables researchers and drug developers to measure brain-specific proteins and biomarkers from a routine blood draw, supporting earlier detection, target-engagement readouts, and treatment-response monitoring across neurodegenerative diseases including ALS, Alzheimer’s disease, and Parkinson’s disease.

ABOUT ALS

Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disease that causes progressive paralysis and is typically fatal within 2–5 years of diagnosis. More than 5,000 people are diagnosed with ALS each year in the U.S. alone, with an estimated annual disease burden of $1 billion. The number of people living with ALS is expected to grow by approximately 24% by 2040 across the U.S. and EU.

ABOUT NEUROSENSE PRIMEC

PrimeC, NeuroSense Therapeutics’ lead drug candidate, is a novel extended-release oral formulation combining two FDA-approved drugs, ciprofloxacin and celecoxib, in a unique fixed-dose combination. PrimeC is designed to synergistically target several mechanisms implicated in ALS, including neuroinflammation, iron accumulation, and impaired RNA regulation, with the goal of slowing disease progression.

MEDIA CONTACT

NeuroDex — Email: info@neurodex.co

https://neurodex.co

Forward-Looking Statements
This press release contains “forward-looking statements” that are subject to risks and uncertainties. Statements regarding the future application of the ExoSORT™ platform, the development of PrimeC, the timing and outcome of clinical trials including a potential Phase 3 (PARAGON) study, and regulatory engagement are forward-looking and based on current expectations. Biomarker findings described herein are exploratory, were generated in part in collaboration with NeuroSense Therapeutics Ltd., and require confirmation in additional studies. Actual results could differ materially from those anticipated. For additional information regarding NeuroSense, PrimeC, and the PARADIGM study, refer to NeuroSense’s filings with the U.S. Securities and Exchange Commission. NeuroDex undertakes no duty to update forward-looking statements except as required by law.

NEWS SOURCE: NeuroDex Inc.

This press release was issued on behalf of the news source (NeuroDex Inc.), who is solely responsible for its accuracy, by Send2Press Newswire. Image, if any, was provided by the news source and not this website or the wire service. Information is believed accurate, as provided by the news source, but is not guaranteed.

To view the original story, visit: https://www.send2press.com/wire/neurodex-exosort-platform-demonstrates-treatment-responsive-blood-based-measurement-of-neuronal-tdp-43-in-people-living-with-als/

99 New Pharmaceutical Biotechnology and Healthcare Projects Drive Major Facility Investments in April 2026

JACKSONVILLE, Fla., May 27, 2026 (SEND2PRESS NEWSWIRE) — Industrial manufacturing activity remained strong in April 2026, led by sustained investment from the pharmaceutical, medical device, biotechnology, and healthcare sectors. Industrial SalesLeads research team identified 60 pharmaceutical, medical device, and biotechnology projects, along with 39 healthcare-related projects, signaling continued demand for facility modernization, expansion, and operational upgrades across the U.S. and Canada.

Image caption: Industrial SalesLeads, Inc.

The following are selected highlights on new Life Science industry news:

LIFE SCIENCES – BY PROJECT TYPE

Pharmaceutical, Medical Device, Biotechnology – 60

Healthcare – 39

LIFE SCIENCES – BY PROJECT LOCATION (TOP 5 STATES)

California – 12

Massachusetts – 11

Virginia – 10

Texas – 8

Michigan – 6

LIFE SCIENCES – BY PROJECT SCOPE/ACTIVITY

Renovation/Equipment Upgrade – 76

Relocation – 60

Expansion/Equipment Upgrade – 14

New Construction – 8

LIFE SCIENCES EQUIPMENT CATEGORIES IN DEMAND

In the month of April, identified life sciences project managers are procuring the following equipment:

80–89%: Lighting (85.9%), Networking/Security Equipment (82.8%)

40–49%: Building Renovation (47.5%)

10–19%: Compressed Air Systems, HVAC Equipment, Mechanical Construction, Fire Protection Equipment, Material Handling/Storage Equipment, Building Construction, Loading Dock Equipment, Conveyors, Heat Exchangers, Control Systems & Instrumentation

9%: Floor Coatings

7%: Air Emissions Control Equipment, Packaging Equipment, Tanks/Vessels – Stainless, Equipment Relocation

TOP 10 TRACKED LIFE SCIENCES PROJECTS

FLORIDA:

Healthcare provider is planning to invest $55 million for new construction of a 14,500sf medical and office in FL. They are currently seeking approval for the project.

GEORGIA:

Healthcare service provider has recently started a 317,000 sf expansion and renovation of their hospital in Cumming, GA. Completion is slated for late 2028.

OHIO:

Biotechnology company is planning to invest $18 million for the expansion and renovation of their warehouse, office, and laboratory facility in OH. They are currently seeking approval for the project. Construction is expected to start in Summer 2026.

MASSACHUSETTS:

Medical device manufacturer is planning for an expansion of their manufacturing facility in MA. They are currently seeking approval for the project.

MINNESOTA:

Pharmaceutical company is planning for the expansion and equipment upgrades on their processing facility in MN. They are currently seeking approval for the project.

MISSOURI:

Pharmaceutical company is planning for the construction of a processing facility in MO. They are currently seeking approval for the project.

NORTH CAROLINA:

Specialty healthcare service provider is planning to invest $2.7 million for the renovation of 10,000 sf of medical and office space in NC. They are currently seeking approval for the project.

NEW JERSEY:

Healthcare service provider is planning to invest $600 million for a 444,000 sf expansion of their hospital in NJ. They are currently seeking approval for the project.

NORTHERN CALIFORNIA:

Healthcare service provider is planning to invest $8 million for the renovation of a recently leased 39,000 sf of medical and office space at CA. They have recently received approval for the project.

NEW YORK:

Healthcare service provider is investing $21 million for the expansion and renovation of their medical and office facilities in NY. Completion is slated for late 2026.

LARGEST PLANNED PROJECT

The largest project is owned by Shine Technologies. Medical isotope technology company is constructing a processing facility in Janesville, WI. Completion is slated for Summer 2027.

ABOUT INDUSTRIAL SALESLEADS, INC.

Since 1959, Industrial SalesLeads, based in Jacksonville, FL is a leader in delivering industrial capital project intelligence and prospecting services for sales and marketing teams to ensure a predictable and scalable pipeline. Our Industrial Market Intelligence, IMI identifies timely insights on companies planning significant capital investments such as new construction, expansion, relocation, equipment modernization and plant closings in industrial facilities. The Outsourced Prospecting Services, an extension to your sales team, is designed to drive growth with qualified meetings and appointments for your internal sales team. Visit us at https://salesleadsinc.com/.

Each month, our team provides hundreds of industrial reports within a variety of industries.

Learn more at:

https://www.salesleadsinc.com/data-solutions/industrial-project-reports/

https://www.salesleadsinc.com/blog/

NEWS SOURCE: Industrial SalesLeads Inc

This press release was issued on behalf of the news source (Industrial SalesLeads Inc), who is solely responsible for its accuracy, by Send2Press Newswire. Image, if any, was provided by the news source and not this website or the wire service. Information is believed accurate, as provided by the news source, but is not guaranteed.

To view the original story, visit: https://www.send2press.com/wire/99-new-pharmaceutical-biotechnology-and-healthcare-projects-drive-major-facility-investments-in-april-2026/

AAAbio Enhances Global Diagnostic Research Capabilities Through Strategic Local Distribution Networks

LA JOLLA, Calif., May 20, 2026 (SEND2PRESS NEWSWIRE) — In a move to significantly reduce lead times for critical diagnostic research components, AAAbio (AAA Biotech, LLC) has announced a major restructuring of its international logistics framework. By empowering a curated network of regional partners, the company is ensuring that its comprehensive suite of Elisa Kits and protein reagents is more accessible to the global scientific community than ever before.

Photo caption: AAAbio Enhances Global Diagnostic Research Capabilities Through Strategic Local Distribution Networks.

This strategic shift addresses one of the most persistent bottlenecks in biomedical research: the delay in acquiring high-sensitivity assay tools. With the rapid pace of modern clinical studies, the ability to receive validated Enzyme-Linked Immunosorbent Assay within days, rather than weeks, can be the deciding factor in the success of a time-sensitive project.

PRECISION AT THE LOCAL LEVEL

The core of this initiative is the decentralization of technical support and product availability. AAAbio recognizes that researchers in different geographic regions face unique regulatory and logistical challenges. By partnering with specialized distributors who understand local market dynamics, the company ensures that every laboratory, regardless of location, receives the same high standard of service and product integrity.

Each authorized distributor in the business’s network undergoes a rigorous selection process. These partners are not merely logistics providers; they are technical extensions of the brand, capable of providing on-the-ground support for complex assay protocols. This ensures that when a researcher utilizes ELISA from the company’s catalog, they have access to a local expert who can assist with optimization and troubleshooting.

BRIDGING THE GAP IN PROTEOMIC RESEARCH

Proteomics remains one of the most challenging frontiers in modern biology. The quantification of specific proteins within complex biological fluids requires tools of the highest specificity. AAAbiotech has spent years refining its manufacturing processes to produce ELISA products that offer industry-leading sensitivity and minimal cross-reactivity.

By making these tools available through a localized distribution model, the company is facilitating a more democratic landscape for scientific discovery. Smaller research institutions and biotech startups, which may have previously struggled with the complexities of international cold-chain shipping, can now source these high-end reagents through domestic channels.

The updated distributor portal on the business website serves as a centralized hub where researchers can identify their nearest authorized provider. This transparency is part of a broader commitment to customer-centric service, allowing scientists to focus on their data rather than their supply chain.

COMMITMENT TO REPRODUCIBILITY

The “reproducibility crisis” in life sciences is often linked to the use of poorly characterized reagents. AAAbiotech addresses this head-on by providing extensive validation data for every product in its inventory. Whether a researcher is looking for sandwich, competitive, or indirect formats, they can be confident that the kits have been tested against rigorous internal standards.

“Our goal is to remove the guesswork from the procurement process,” said the Director of Global Operations at AAAbiotech. “By strengthening our ties with local distributors, we are ensuring that the cold-chain requirements for our Elisa Kits are strictly maintained from our facility to the customer’s bench. This level of oversight is essential for maintaining the biological activity of the antibodies and proteins included in our kits.”

Learn more: https://www.aaabiotech.com/elisa-kits

FUTURE-PROOFING THE SUPPLY CHAIN

As the biotechnology sector continues to expand globally, particularly in regions like Southeast Asia and South America, the demand for reliable diagnostic tools is surging. AAAbio is actively seeking to expand its footprint in these emerging markets to support the next generation of global health breakthroughs.

ABOUT AAABIO

Headquartered in the biotech hub of La Jolla, California, AAAbio (AAA Biotech, LLC) is a premier manufacturer and supplier of high-quality life science reagents. The company’s portfolio includes an expansive range of antibodies, recombinant proteins, and Enzyme-Linked Immunosorbent Assay Kits designed to meet the exacting standards of the global research community. Through a combination of innovative manufacturing and a robust international distribution network, the company is dedicated to accelerating the pace of discovery in human health and disease.

For more information and queries:

Visit the company’s official website: https://www.aaabiotech.com/.

Tel: +1 (619) 604-9440
Fax: +1 (619) 604-9441
Toll Free: +1-800-604-9114
Email: info@aaabiotech.com
Tech Support: tech@aaabiotech.com

Visit us on social media:

Instagram – https://www.instagram.com/aaabiotech/

Facebook – https://www.facebook.com/people/AAA-Biotech/61578212701968/

X – https://x.com/aaabiotech1

Mailing Address: AAA Biotech, LLC, PO Box 1697, La Jolla, CA 92038

MEDIA ONLY CONTACT
Cynthia Lee
+1 619-604-9440
info@aaabiotech.com

MULTIMEDIA
Photo link for media: https://www.Send2Press.com/300dpi/26-0520-s2p-aaabio-300dpi.webp

Photo caption: AAAbio Enhances Global Diagnostic Research Capabilities Through Strategic Local Distribution Networks

***
UPDATED 5pm PDT to fix an inadvertent typographical error missed at time of publication.

NEWS SOURCE: AAA Biotech LLC (AAAbio)

This press release was issued on behalf of the news source (AAA Biotech LLC (AAAbio)), who is solely responsible for its accuracy, by Send2Press Newswire. Image, if any, was provided by the news source and not this website or the wire service. Information is believed accurate, as provided by the news source, but is not guaranteed.

To view the original story, visit: https://www.send2press.com/wire/aaabio-enhances-global-diagnostic-research-capabilities-through-strategic-local-distribution-networks/

Neurotech Reports Announces Thomas Stieglitz, Ph.D., as Keynote Speaker for the Second Annual Neurotech Leaders Forum imec

SAN FRANCISCO, Calif., May 14, 2026 (SEND2PRESS NEWSWIRE) — Neurotech Reports today announced that Thomas Stieglitz, Ph.D., a globally recognized expert in neural engineering and implantable neurotechnology, will keynote the Second Annual Neurotech Leaders Forum imec, taking place June 23-24, 2026, in Leuven, Belgium.

Photo caption: Thomas Stieglitz, Ph.D., will keynote the Second Annual Neurotech Leaders Forum imec.

The Neurotech Leaders Forum brings together senior executives, investors, researchers, clinicians, and technology developers working at the forefront of neurotechnology, bioelectronic medicine, and brain-computer interface innovation. The event serves as a platform for examining emerging technologies, commercialization trends, investment activity, and the evolving direction of the neurotech industry across Europe and internationally.

“Dr. Thomas Stieglitz represents the kind of visionary leadership that continues to drive the neurotechnology field forward,” said James Cavuoto, editor and publisher of Neurotech Reports. “His perspective on the convergence of engineering, neuroscience, and clinical application will provide tremendous value for attendees from across the neurotech ecosystem.”

“Advances in neural interfaces and bioelectronic medicine are creating entirely new possibilities for treating neurological disorders and restoring function,” said Dr. Stieglitz. “I am honored to participate in this year’s Neurotech Leaders Forum imec and contribute to the conversation about the future of neurotechnology.”

Dr. Stieglitz is widely recognized for his contributions to neural interface technologies and implantable systems aimed at restoring and modulating nervous system function. Throughout his career, he has combined academic leadership with entrepreneurial innovation, co-founding companies focused on neural implants and neuromodulation therapies. He has authored more than 200 scientific journal articles, contributed extensively to conference literature, and is named on dozens of patents spanning neurotechnology and biomedical engineering.

Launched in 2025, the Neurotech Leaders Forum imec has quickly become a key meeting point for neurotechnology executives, researchers, and investors from across Europe and North America. The 2026 Forum will bring together leaders in neurostimulation, brain-computer technologies, implantable devices, AI-enabled neurotechnology, and investment at imec, one of Europe’s leading research and innovation centers.

Additional information and registration details are available at: https://www.neurotechreports.com/pages/leadersforum-europe.html

More information about imec is available at: https://www.imec-int.com/

ABOUT NEUROTECH REPORTS

Neurotech Reports, part of Cambridge Innovation Institute, is a leading source of market research, industry analysis, and business news covering neurotechnology, neuromodulation, and bioelectronic medicine. Through its publications and executive conferences, the company provides insights into emerging technologies, commercial trends, and investment activity shaping the global neurotech industry. Learn more: https://www.neurotechreports.com/

MULTIMEDIA:

Photo link for media: https://www.Send2Press.com/300dpi/26-0514-s2p-stieglitz-300dpi.webp

Photo caption: Thomas Stieglitz, Ph.D., will keynote the Second Annual Neurotech Leaders Forum imec

LOGO: https://www.neurotechreports.com/images/nlf-imecFlag-horiz.png

NEWS SOURCE: Neurotech Reports

This press release was issued on behalf of the news source (Neurotech Reports), who is solely responsible for its accuracy, by Send2Press Newswire. Image, if any, was provided by the news source and not this website or the wire service. Information is believed accurate, as provided by the news source, but is not guaranteed.

To view the original story, visit: https://www.send2press.com/wire/neurotech-reports-announces-thomas-stieglitz-ph-d-as-keynote-speaker-for-the-second-annual-neurotech-leaders-forum-imec/

ViewTech Borescopes to Demonstrate Clean-In-Place Visual Inspection Solutions at INTERPHEX 2026

NEW YORK, N.Y., April 20, 2026 (SEND2PRESS NEWSWIRE) — ViewTech Borescopes, a leading provider of remote visual inspection (RVI) equipment, is returning to exhibit at INTERPHEX, the premier global pharma and biotechnology event. Attendees are invited to visit the ViewTech Borescopes booth 1943 to experience live demonstrations of its industry-leading video borescope technology designed to improve inspection efficiency, safety, and compliance in critical pharmaceutical manufacturing environments.

Image caption: ViewTech Borescopes showcases its advanced video borescope technology for pharmaceutical and biotechnology applications at INTERPHEX (Booth 1943), highlighting solutions designed to improve inspection efficiency, safety, and compliance in critical manufacturing environments.

At INTERPHEX, ViewTech will showcase its latest lineup of high-resolution video borescopes engineered for precise, non-destructive inspection in pharmaceutical processing equipment, cleanrooms, and hard-to-reach areas. These tools enable manufacturers to identify potential issues without disassembly, reducing downtime and supporting strict regulatory standards.

“INTERPHEX provides an excellent opportunity to connect with pharmaceutical professionals focused on quality, and safety,” said Chris Courtright, Sales Consultant at ViewTech Borescopes. “Our Ultraviolet video borescope solutions are designed to evaluate their clean-in-place (CIP) processes and riboflavin coverage testing, and we’re excited to demonstrate how our technology delivers measurable value.”

Read more about INTERPHEX 2026: https://www.viewtech.com/about-us/tradeshows/interphex-2026/

TRY BEFORE YOU BUY

In addition to live demonstrations during INTERPHEX 2026, ViewTech offers an exclusive No-Cost, No-Obligation Demo Program. This program allows end-users the opportunity to evaluate a ViewTech video borescope at their own facility on their own equipment, ensuring the technology meets their specific inspection requirements before any financial commitment.

VJ-3 AND VJ-4 VIDEO BORESCOPE

The VJ-3 and VJ-4 mechanical articulating video borescopes are nondestructive visual testing instruments used for the remote visual inspection of machinery, equipment, and components. With diameters as small as 0.85mm, the VJ-3 and VJ-4 facilitate the visual recording and photo documentation of an inspection and components in areas that are otherwise inaccessible or require significant effort and expense to access directly. The VJ-3 and VJ-4 video borescopes consist of two modules integrated into one system: an insertion tube with distally mounted camera/LEDs and the base unit with control panel, LCD monitor, power source, and all necessary circuitry.

ABOUT VIEWTECH BORESCOPES

ViewTech Borescopes, founded as RF System Lab in 2008, is North America’s top seller of video borescopes. Their first product, the VJ borescope, set a new standard for portability, ergonomics, and ease-of-use, with its industry-first mechanical, joystick-controlled articulation.

Learn more: https://www.viewtech.com/

MULTIMEDIA

Image link for media: https://www.Send2Press.com/300dpi/26-0420-s2p-vtech-300dpi.webp

Logo link: https://www.viewtech.com/wp-content/uploads/view-tech-logo-h-650.png

NEWS SOURCE: ViewTech Borescopes

This press release was issued on behalf of the news source (ViewTech Borescopes), who is solely responsible for its accuracy, by Send2Press Newswire. Image, if any, was provided by the news source and not this website or the wire service. Information is believed accurate, as provided by the news source, but is not guaranteed.

To view the original story, visit: https://www.send2press.com/wire/viewtech-borescopes-to-demonstrate-clean-in-place-visual-inspection-solutions-at-interphex-2026/

BioAustinCTX Announces Leadership Transition

AUSTIN, Texas, March 18, 2026 (SEND2PRESS NEWSWIRE) — BioAustinCTX today announced that Scott Collins, PhD, has transitioned from his role as President at the end of February after more than a decade of leadership supporting the growth of the Central Texas life sciences ecosystem.

Image caption: BioAustinCTX.

During his tenure over the past decade, Dr. Collins helped guide BioAustinCTX through a period of significant expansion for the region’s biotechnology and life science community. Under his leadership, the organization strengthened its role as a connector across startups, established companies, academic institutions, investors, and economic development partners, helping foster collaboration and visibility across the ecosystem.

“Serving as President of BioAustinCTX has been one of the great privileges of my professional career,” said Dr. Collins. “I am proud of the progress our community has made and look forward to continuing to support the organization as Ambassador and Past President while focusing on advancing deep technology and biotechnology innovation in the Central Texas region.”

Following this transition, Dr. Collins will remain actively engaged with BioAustinCTX in an Ambassador and Past President capacity, supporting the organization’s mission and ongoing initiatives.

As BioAustinCTX looks ahead, the organization remains focused on strengthening the connectivity, competitiveness, and growth of the Central Texas life sciences sector. The Board of Directors is committed to building on the strong foundation established to date and will share additional updates regarding leadership and strategic priorities in the coming weeks.

BioAustinCTX thanks Dr. Collins for his service and leadership and looks forward to continued collaboration as the organization enters its next phase.

About BioAustinCTX

BioAustinCTX is a nonprofit industry organization dedicated to advancing the life sciences ecosystem in Central Texas. Through collaboration, education, networking, and strategic engagement, BioAustinCTX supports entrepreneurs, researchers, companies, and partners working to bring life-changing technologies to market. Learn more at https://bioaustinctx.com/.

NEWS SOURCE: BioAustinCTX

This press release was issued on behalf of the news source (BioAustinCTX), who is solely responsible for its accuracy, by Send2Press Newswire. Image, if any, was provided by the news source and not this website or the wire service. Information is believed accurate, as provided by the news source, but is not guaranteed.

To view the original story, visit: https://www.send2press.com/wire/bioaustinctx-announces-leadership-transition/

Iota Biosciences Founder to Keynote 2026 Bioelectronic Medicine Forum in NYC

European firms Coherence Neuro and Graphenicalab will present at the meeting, as will U.S. startup firm Spiro Medical

NEW YORK, N.Y., March 5, 2026 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that the Ninth Annual Bioelectronic Medicine Forum will take place on April 14, 2026. The one-day event will be held at the New York Academy of Medicine in Manhattan.

Photo caption: iota Biosciences CEO Michel Maharbiz will keynote the 2026 Bioelectronic Medicine Forum in New York City on April 14.

Michel Maharbiz, CEO of iota Biosciences, will keynote the conference. The innovative bioelectronic medicine firm spun off from UC Berkeley in 2017 and was acquired by Astellas, a global pharmaceutical company, in 2021 in a deal worth several hundred million dollars. Until 2021, Michel was a full professor and is now an adjunct professor with the department of electrical engineering and computer science at the University of California, Berkeley. Prof. Maharbiz received his B.S. from Cornell University and his Ph.D. from the University of California, Berkeley under nanotechnologist Prof. Roger T. Howe and synthetic biologist Jay D. Keasling.

European firms Coherence Neuro and Graphenicalab will present at the meeting, as will U.S. startup firm Spiro Medical. Venture capital professionals Jeff Chu from Features Capital, Allan Gobbs from ATEM Capital, and Jeffrey Scott Cohen from Ladenburg Thalmann & Co will participate in panels devoted to investment in bioelectronic medicine.

There will also be several informative panel discussions on key topics such as novel diagnostics, emerging technologies, and reimbursement. Neurotech Reports editors James Cavuoto, Jeremy Koff, Victor Pikov, and JoJo Platt will moderate sessions at the event.

Also at the event, Jennifer French, executive director of Neurotech Network, will sit down for a fireside chat with Neurotech Reports editor James Cavuoto for a discussion on the history of the bioelectronic medicine industry.

Cirtec Medical is the Platinum Sponsor of the conference. MST is the Gold Sponsor. Osypka is the Silver Sponsor.

“Bioelectronic medicine merges some of the best attributes of biopharma and neurotech approaches to treating systemic disorders,” said James Cavuoto, editor and publisher at Neurotech Reports. “This ninth-annual conference will be a key meeting place for entrepreneurs and executives helping to build this industry.”

For more information on the 2026 Bioelectronic Medicine Forum, contact Neurotech Reports at 415 546 1259 or visit this link: http://neurotechreports.com/pages/bioelectronic-medicine-forum.html.

MULTIMEDIA

Photo link for media: https://www.Send2Press.com/300dpi/26-0305-s2p-Maharbiz-300dpi.webp

Photo caption: iota Biosciences CEO Michel Maharbiz will keynote the 2026 Bioelectronic Medicine Forum in New York City on April 14.

LOGO links:

[1] https://neurotechreports.com/images/bmflogo.jpg

[2] https://www.neurotechreports.com//images/neurotech_business_SimpleBug.png

NEWS SOURCE: Neurotech Reports

To view the original story, visit: https://www.send2press.com/wire/iota-biosciences-founder-to-keynote-2026-bioelectronic-medicine-forum-in-nyc/

HLA Protein Technologies Debuts sHLA-G Monomer and Tetramer Portfolio for High-Fidelity Checkpoint Biology, Target Validation, and Assay Development

OKLAHOMA CITY, Okla., Nov. 19, 2025 (SEND2PRESS NEWSWIRE) — HLA Protein Technologies, Inc. (formerly Pure Protein, LLC) today announced the commercial launch of its new soluble HLA-G (sHLA-G) product portfolio, marking an expansion of its next-generation HLA research tools.

Image caption: HLA Protein Technologies, Inc.

HLA-G PORTFOLIO HIGHLIGHTS

The Company’s broad new sHLA-G platform includes biotinylated monomers, fluorophore-labeled tetramers, and peptide-loaded complexes, produced using a proprietary mammalian expression system to ensure authentic folding, natural glycosylation, and physiologically relevant epitope presentation.

These reagents enable high-throughput screening, antibody validation, and translational research applications such as:

Drug discovery and immune checkpoint studies
Diagnostic assay development (ELISA, BLI, SPR)
Transplantation and autoimmunity research

HLA-G BIOLOGY AND RESEARCH IMPACT

HLA-G is a non-classical MHC Class I molecule recognized as a key immune checkpoint regulator. Its unique tolerogenic properties and restricted polymorphism make it critical for studies in immune tolerance, transplantation, oncology, autoimmunity, and infectious disease. Soluble isoforms of HLA-G exert powerful immunosuppressive effects, influencing NK cells, T cells, B cells, and dendritic cells – critical pathways for therapeutic development.

DEDICATED FOCUS ON HLA PROVIDES VALUE TO RESEARCHERS

Accelerated R&D: Ready-to-use, biologically accurate HLA reagents can accelerate project timelines.
World-Class Data Quality: Native-like sHLA-G molecules yield more predictive and reproducible results than non-soluble HLA.
Translational Confidence: sHLA closely reflects human biology, bridging the gap between bench research and clinical application.
Regulatory Readiness: Standardized, validated products support compliance and documentation for therapeutic development.

“Our sHLA-G portfolio marks a breakthrough for advancing next-generation immunotherapies, enabling researchers to decode and harness HLA-G–mediated immune regulation in cancer and transplantation.,” said Dr. Rico Buchli, Chief Scientist at HLA Protein Technologies. “By combining biological fidelity with scalable production, we’re providing tools that accelerate discovery and clinical translation.”

AVAILABILITY

The sHLA-G product line is now available for order at https://www.hlaprotein.com/products/hla-class-i/hla-g.

Custom projects and collaborations are supported through dedicated technical and licensing teams.

ABOUT HLA PROTEIN TECHNOLOGIES, INC.

HLA Protein Technologies, Inc., based in Oklahoma City, Oklahoma, specializes in high-purity HLA proteins, engineered cell lines and custom assay development.

With a focus on immunology and oncology, the company provides HLA-based reagents and services that enable discovery, lead validation and translational research. HLA Protein Technologies serves leading pharma, diagnostic and research customers in more than 20 countries.

Public and media queries: https://www.hlaprotein.com/contact-us

MULTIMEDIA:

Logo link for media: https://www.Send2Press.com/300dpi/25-0930-s2p-hlaprot-300dpi.webp

NEWS SOURCE: HLA Protein Technologies Inc.

This press release was issued on behalf of the news source (HLA Protein Technologies Inc.), who is solely responsible for its accuracy, by Send2Press Newswire. Image, if any, was provided by the news source and not this website or the wire service. Information is believed accurate, as provided by the news source, but is not guaranteed.

To view the original story, visit: https://www.send2press.com/wire/hla-protein-technologies-debuts-shla-g-monomer-and-tetramer-portfolio-for-high-fidelity-checkpoint-biology-target-validation-and-assay-development/

HLA Protein Technologies Announces Next-Gen HLA Product Lines and Strategic Investment

OKLAHOMA CITY, Okla., Sept. 30, 2025 (SEND2PRESS NEWSWIRE) — HLA Protein Technologies, Inc. (formerly Pure Protein, LLC) reports that its new manufacturing expansion is positioned to support the Company’s growth. A new product line launch, a strategic investment led by a private investor group; and a corporate rebrand to HLA Protein Technologies, reflects the company’s expanded focus on advanced immunology and oncology research tools.

Image caption: HLA Protein Technologies, Inc.

The new investment will fund accelerated product development and expanded manufacturing capacity at the company’s Oklahoma City headquarters, with additional hiring across R&D, bioprocess and commercial operations. HLA Protein Technologies will scale production capacity, implement expanded QC/QA frameworks and enhance GMP‑adjacent processes suitable for research‑use‑only (RUO) products.

The company expects to add roles across protein biochemistry, cell biology, manufacturing operations and commercial support. Facility enhancements will prioritize throughput, reproducibility and documentation standards to align with customer expectations in biopharma R&D.

And, the rebrand to HLA Protein Technologies unifies the company’s legacy of protein engineering with its expanded mission: delivering best‑in‑class HLA research tools and services to customers across biopharma, diagnostics and translational research. This transition establishes a brand identity that mirrors the company’s core scientific strengths and customer value proposition in HLA‑based research tools. The new name and visual identity will roll out across product labels, documentation and digital properties over the coming weeks.

“This is a pivotal moment in our company’s evolution,” said Dr. Rico Buchli, Chief Scientist at HLA Protein Technologies. “Our new HLA portfolio pairs rigorously characterized reagents with custom services that help biopharma teams accelerate target discovery and validation, immune monitoring and mechanism‑of‑action studies. The rebrand reflects our commitment to leadership in HLA‑enabled solutions.”

Anchored by two decades of expertise in soluble HLA engineering and peptide–MHC technologies, the new product lines will feature next‑generation Class I and Class II HLA tetramers, new product formats and custom peptide‑loaded complexes designed for high‑throughput discovery, screening and translational studies.

This portfolio will be complemented by custom assay development and engineered cell line services to support biopharma and academic partners advancing immunotherapies and vaccine research. These new products will complement the Company’s existing portfolio of more than 275 HLA Class I and Class II alleles; it will be made available to the scientific community at https://hlaprotein.com/.

“Oklahoma’s life sciences ecosystem is gaining momentum, and HLA Protein Technologies’ growth exemplifies that trajectory,” said Michelle Gregory, Director, Life Science Oklahoma. “The company’s expansion and investment in local manufacturing aligns with our mission to advance U.S.-based innovation and bioproduction.”

About HLA Protein Technologies, Inc.

HLA Protein Technologies, Inc., based in Oklahoma City, Oklahoma, specializes in high‑purity HLA proteins, engineered cell lines and custom assay development. With a focus on immunology and oncology, the company provides HLA‑based reagents and services that enable discovery, lead validation and translational research. HLA Protein Technologies serves leading pharma, diagnostic and research customers in more than 20 countries.

Public and media queries: https://www.hlaprotein.com/contact-us

MULTIMEDIA:

Logo link for media: https://www.Send2Press.com/300dpi/25-0930-s2p-hlaprot-300dpi.webp

NEWS SOURCE: HLA Protein Technologies Inc.

To view the original story, visit: https://www.send2press.com/wire/hla-protein-technologies-announces-next-gen-hla-product-lines-and-strategic-investment/

Two Prominent Professors to Keynote 25th Annual Neurotech Leaders Forum

SAN FRANCISCO, Calif., Aug. 11, 2025 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the publisher of the Neurotech Business Report newsletter, announced that two prominent figures in the field of neurotechnology will keynote the 2025 Neurotech Leaders Forum, which takes place November 5-6 in San Francisco. Edward Chang, chair of the department of neurological surgery at UC San Francisco, will discuss future applications of implanted brain sensing and stimulation devices.

Image caption: Prof. Edward Chang, M.D., from UC San Francisco (L) and J. Thomas Mortimer, Ph.D., Emeritus from Case Western University (R) will keynote the 2025 Neurotech Leaders Forum in San Francisco.

J. Thomas Mortimer, emeritus professor of biomedical engineering at Case Western Reserve University, will discuss his history as a pioneer developing implanted neurostimulation systems for chronic pain, diaphragm pacing, and bladder control.

The 25th annual event will also feature sessions devoted to the business of neuromodulation, the investment outlook for neurotechnology, the convergence of AI and BCI technologies, new realities in regulatory and reimbursement policies, and several other topics. Neurotech Reports editors James Cavuoto, Jeremy Koff, JoJo Platt, and Victor Pikov will moderate panel discussions with key industry leaders.

Several panelists and presenters were recently added to the agenda for the two-day conference. New speakers include Ryan Field, CEO of Kernel; Andreas Forland, CEO of Cognixion; and Oliver Armitage, newly appointed vice president of Axoft. Venture capital professionals participating in the meeting include Mir Imran, managing partner at InCube Ventures, and Lu Zhang, founder and managing partner of Fusion Fund.

Among the new presenters this year are Emile Radyte, CEO of Samphire Neuroscience in the U.K., which has developed a wearable neuromodulation device for treatment of PMS and menstrual pain and Tetiana Aleksandrova, CEO of Subsense, Inc., which is developing a nonsurgical nanoparticle-based BCI system.

The Platinum Sponsor at this year’s event is Cirtec Medical. Micro Systems Technology is the Gold Sponsor. Silver sponsors include Velentium and Valtronic.

“As we celebrate our 25th year covering the neurotechnology industry, it’s gratifying to have Prof. Mortimer, one of the founders of the field, and Prof. Chang, one of the most promising researchers and entrepreneurs, talk about the past and future of our industry,” said James Cavuoto, editor and publisher of Neurotech Reports.

Neurotech Reports has extended the early-bird registration deadline until September 12, 2025.

Also, Neurotech Reports still has openings for a small number of startup and early-stage firms who would like to present during one of two Entrepreneur Panels at the conference.

To apply, visit this link: https://www.neurotechreports.com/pages/nlf-presenter-application.html

For more information, contact Neurotech Reports at 415 546 1259 or visit https://www.neurotechreports.com/.

MULTIMEDIA:

Image link for media: https://www.Send2Press.com/300dpi/25-0811-s2p-ntpchangmortimer-300dpi.jpg

Neurotech Reports logo: https://www.neurotechreports.com//images/neurotech_business_SimpleBug.png

NEWS SOURCE: Neurotech Reports

To view the original story, visit: https://www.send2press.com/wire/two-prominent-professors-to-keynote-25th-annual-neurotech-leaders-forum/

Zeteo Biomedical Secures Global Patents for Nasal and Ophthalmic Drug Delivery Device Innovations

CEDAR PARK, Texas, June 11, 2025 (SEND2PRESS NEWSWIRE) — Zeteo Biomedical, a privately held biomedical device company, today announced the issuance of new patents in the United States and European Union for its advanced drug delivery technologies. The patents, titled “Cartridge Devices for Administration of a Medicament” (U.S. Patent No. 12329949) and “Hand-Operated Devices for Administration of a Medicament” (EU Patent No. 3946526), further strengthen Zeteo’s ZTech™ delivery platform portfolio for the administration of drugs and biologics via nasal, ophthalmic, and sublingual routes.

Image caption: Zeteo Biomedical.

These patented innovations advance Zeteo’s ZTech-L™ and ZTech-P™ delivery systems, which include both single-use disposable and multi-dose, cartridge-reloadable handheld devices. The platforms support the administration of therapeutics in both liquid and dry powder formulations, including vaccines, biologics, and specialty drugs. Nasal delivery, in particular, is emerging as a highly effective, non-invasive alternative for treating conditions such as pain, emesis, seizures, neurodegenerative and autoimmune disorders, infectious diseases, and bioterror threats.

“We are seeing increasing global demand for metered-dose nasal, ophthalmic, and sublingual delivery devices that are compact, intuitive, and suitable for self-administration,” said Timothy Sullivan, CEO of Zeteo Biomedical. “A unique feature that sets our device technology apart is its ability to function reliably in any physical orientation, making it ideal for medication delivery in both terrestrial and space-based microgravity environments. This capability opens exciting new frontiers for Zeteo including applications in space-based healthcare.”

Zeteo’s integrated delivery platforms and technical services streamline the development and commercial-scale production of patient-centric drug/device combination products for pharmaceutical and biotech partners. This focus on patient-friendly design improves treatment adherence and medical outcomes, while enhancing product differentiation and brand value for manufacturers.

Zeteo’s platform technologies are designed to meet the evolving demands of global and interstellar healthcare markets, delivering precision, performance, and portability for the next-generation of therapeutic drug/device combination products.

About Zeteo Biomedical LLC

Zeteo Biomedical is a Texas-based medical device company focused on the development and commercialization of advanced drug and biologic delivery systems. The company specializes in intranasal, ophthalmic, and sublingual delivery technologies designed to improve patient outcomes through precision dosing, portability, and ease of use. Zeteo’s proprietary platforms are supported by an extensive patent portfolio and a range of product development services tailored to accelerate time to market for pharmaceutical and biotech clients worldwide.

To learn more, visit https://zeteobiomed.com/.

MEDIA CONTACT:
Cathy Diehl
Zeteo Biomedical LLC
+(1) 512-614-0144
zeteo@zeteobiomed.com

*LOGO link for media: https://www.send2press.com/300dpi/20-1117s2p-zeteo-biomedical-300dpi.jpg

NEWS SOURCE: Zeteo Biomedical LLC

To view the original story, visit: https://www.send2press.com/wire/zeteo-biomedical-secures-global-patents-for-nasal-and-ophthalmic-drug-delivery-device-innovations/

Imaging with Precision: Amerigo Scientific Announces Different-Sized Bioconjugated Fluorescent Nanodiamonds

NEW YORK, N.Y., May 9, 2025 (SEND2PRESS NEWSWIRE) — Amerigo Scientific unveils its line of different-sized bioconjugated fluorescent nanodiamonds (FNDs), designed to redefine precision in cellular and in vivo imaging. These bioconjugated FNDs are provided to address critical challenges in high-resolution diagnostics, targeted drug delivery, and real-time biological tracking, positioning itself as a game-changer for researchers and scientists alike.

Image caption: Amerigo Scientific.

FNDs are emerging as efficient and safe candidates for cellular imaging, due to their bright fluorescence, high photostability with sufficiently long lifetime, and excellent biocompatibility. For in vivo work, FNDs have been recognized as a safe and biocompatible material in many studies.

Amerigo Scientific provides nanodiamonds featuring three distinct fluorescence properties: NV centers emitting red-to-near-infrared fluorescence, NVN centers exhibiting green fluorescence, and novel hybrid particles containing both NV and NVN centers within a single structure, which display visible yellow fluorescence. These hybrid particles enable ratiometric fluorescence calibration by monitoring the intensity ratio between green and red spectral emissions. This capability facilitates particle tracking even under conditions of high background fluorescence.

To power up imaging with precision, Amerigo Scientific’s range of bioconjugated FNDs is engineered in multiple sizes (40–140 nm), having an outstanding profile of uniformity, stability, and scalability, enabling researchers to select optimal dimensions for specific imaging depths and resolutions. Smaller particles excel in single-molecule tracking, while larger variants enhance contrast in deep-tissue imaging. If small particles are necessary for research, 40nm particles could be the best choice in terms of both brightness and size. For initial users, it is generally advised to begin with larger particle sizes (approximately 100 nm or above) to assess whether fluorescent nanodiamonds can deliver sufficient contrast for the intended application.

In conclusion, Amerigo Scientific offers highly sensitive, precision-engineered fluorescent nanodiamonds tailored for advanced imaging applications. Its FNDs combine exceptional brightness, photostability, and biocompatibility, making them ideal for demanding research in super-resolution microscopy, single-molecule tracking, and deep-tissue imaging. With rigorous quality control, Amerigo ensures batch-to-batch consistency, critical for reproducible experiments.

Whether for high-resolution studies or deep imaging, Amerigo Scientific provides reliable, cutting-edge FND solutions backed by strong technical support, accelerating breakthroughs in life sciences and nanomedicine.

Learn more: https://www.amerigoscientific.com/bioconjugated-fluorescent-nanodiamonds.html

About Amerigo Scientific:

Amerigo Scientific, as a recognized distributor in the United States, collaborates closely with leading manufacturers worldwide and invites cooperation from all companies and institutions in the area of reagents, kits, antibodies, and many other products for life science, biochemistry, and biotechnology. Its professional team is equipped with excellent technical support and thoughtful customer service. As most of its employees have earned a graduate (Ph.D. or M.S.) degree in life science, they can comprehend customers’ questions or concerns and are always ready to provide individualized customer service of high standards.

Media Contact and more information:
Contact Name: Phoebe Davis
Contact Email: contact@amerigoscientific.com
Contact Phone: 1-516-665-1612

Website: https://www.amerigoscientific.com/

Address: Hauppauge, NY 11788, USA

NEWS SOURCE: Amerigo Scientific

This press release was issued on behalf of the news source (Amerigo Scientific), who is solely responsible for its accuracy, by Send2Press Newswire. Image, if any, was provided by the news source and not this website or the wire service. Information is believed accurate, as provided by the news source, but is not guaranteed.

To view the original story, visit: https://www.send2press.com/wire/imaging-with-precision-amerigo-scientific-announces-different-sized-bioconjugated-fluorescent-nanodiamonds/

Redox Therapeutics Signs Exclusive License Agreement with The Curators of the University of Missouri to Create Filtration Technology to Address Healthcare and Environmental Needs

PHILADELPHIA, Pa., April 29, 2025 (SEND2PRESS NEWSWIRE) — Redox Therapeutics announces the signing of an exclusive license agreement with The Curators of the University of Missouri acting by and through the Missouri University of Science and Technology (Missouri S&T) for a patented polymer nanoparticles technology designed for endotoxin removal from fluids such as water, protein solutions and plasma. Currently, it’s seeking partners in the healthcare and wastewater industries to bring this technology to the forefront of effective and affordable treatment for sepsis.

Image caption: Redox Therapeutics logo.

Sepsis is a leading cause of death. The World Health Organization reports that endotoxin is the main contributing factor in sepsis and septic shock, complex syndromes of multiorgan failure resulting in the annual death of more than 11 million people. And the Association of American Medical Colleges says that sepsis is the third leading cause of death in U.S. hospitals.

An abstract in the National Library of Medicine reports that despite all efforts of experimental and clinical research during the last three decades, the ability to positively influence course and outcome of the syndrome remains limited.

Redox Therapeutics is looking to close the therapeutic gap by developing a blood filtration system that features the licensed polymer nanoparticles, which proved to remove up to 100 percent endotoxin from water and protein solutions in experiments conducted at Missouri S&T and published in peer-reviewed industry journals.

It also seeks to address another area of global health concern – the presence of endotoxin in contaminated industrial and wastewater systems. The presence of endotoxin in food, water and manufactured biomedical drugs is a major concern for human health and safety.

Redox Therapeutics seeks to partner with water filtration industry leaders and implement the endotoxin removal technology in their product lines, so that it contributes to lowering the incidence of sepsis.

Leonard Neatu, MD, founder, president and CEO of Redox Therapeutics, says he’s excited to have the opportunity to license and bring to market this outstanding nanoparticle technology. He has more than 25 years of entrepreneurial experience in the healthcare industry and as an independent scientist is part of a collective effort to precipitate a major shift in understanding as it regards the human disease occurrence and healing process.

He adds that this technology is not only extremely effective in removing endotoxin, but it’s also cost-effective.

“We’re confident that this technology will help to save lives, many of them, and I’m grateful for having the opportunity to contribute to this prospect,” he says.

Kamal H. Khayat, Vice Chancellor for Research and Innovation at Missouri S&T, looks forward to a long and successful relationship with Redox Therapeutics (Redox).

“S&T is thrilled to license this nanoparticle filtration technology to Redox so that its benefits can be used to help society,” he says.

About Redox Therapeutics, Inc.

Redox Therapeutics, Inc. is a biomedical technology startup company founded by Dr. Leonard Neatu, whose work is focused on the field of redox biology and its implications in the development and progression of diseases. The company’s mission is to translate the intellectual property, acquired over 10 years of integrative research, into the development and manufacturing of a series of filtration devices that aim to restore homeostasis in biological systems through complex and innovative treatments of plasma and cerebrospinal fluid.

About Missouri S&T

Missouri University of Science and Technology (Missouri S&T) is a STEM-focused research university of over 7,000 students located in Rolla, Missouri. Part of the four-campus University of Missouri System, Missouri S&T offers over 100 degrees in 40 areas of study and is among the nation’s top public universities for salary impact, according to the Wall Street Journal.

MORE INFORMATION

Redox Therapeutics: https://redoxtherapeutics.com/

Missouri University of Science and Technology: https://www.mst.edu/

Pain Neuromodulation Market to Reach $6.5 Billion by 2030

The market includes spinal cord stimulation (SCS) systems as well as peripheral nerve stimulation (PNS) systems

SAN FRANCISCO, Calif., March 31, 2025 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the publisher of the newsletter Neurotech Business Report, announced the availability of a new market research report that forecasts the growth of the worldwide market for implanted pain neuromodulation systems. According to the newly published report, “The Market for Implanted Pain Neuromodulation Systems: 2025-2030,” the worldwide market will be $3.37 billion in 2025, growing to $6.49 billion by 2030, which represents a 12% compound annual growth rate. The market includes spinal cord stimulation (SCS) systems as well as peripheral nerve stimulation (PNS) systems. Neurotech Reports estimates that the PNS market will grow at a 29% CAGR between 2025 and 2030.

Image caption: Neurotech Reports recently released its latest forecast on the growth of the market for implanted pain neuromodulation systems, which include spinal cord stimulation (SCS) and peripheral nerve stimulation (PNS) systems.

Major players in the SCS market include Medtronic, Abbott, Boston Scientific, and Nevro, which was recently acquired by medtech manufacturer Globus Medical. The report includes Neurotech Reports editors’ analysis of the impact of this transaction on the competitive landscape of the SCS market. Newer players in the SCS market include Saluda Medical, which pioneered the concept of closed-loop SCS, and European firm Biotronik.

Leading competitors in the PNS space include Curonix, which markets an injectable pain stimulator, SPR, which markets a percutaneous system, Nalu Medical, Bioventus, and Mainstay Medical, which markets a restorative neuromodulation system for treatment of back pain of mechanical origin. Several startup and emerging firms are poised to enter the space in coming years.

The Market for Implanted Pain Neuromodulation Systems: 2025-2030 was authored by the editors of Neurotech Reports, including James Cavuoto, Jeremy Koff, Victor Pikov, and others. Now in its 25th year of publishing, Neurotech Reports is the longest-serving publishing and market-intelligence firm serving the neuromodulation market.

The report includes up-to-date information obtained at the 2025 meeting of the North American Neuromodulation Society, the 2025 JP Morgan Healthcare Conference, and other recent events. Data for the report was obtained from dozens of confidential interviews with key executives in the industry as well as numerous implanters of neuromodulation devices.

“There are a number of market research reports that claim to offer insight on the neuromodulation industry. But neuromodulation industry professionals should ask if they’ve ever seen the authors of those reports at key conferences such as NANS, INS, LSI. Neurotech Reports editors have been covering these events for 25 years and know the key players inside and out,” said James Cavuoto, editor and publisher of Neurotech Reports. “This report draws on our 25 years of reporting on the neuromodulation industry.”

Learn more: https://www.neurotechreports.com/pages/mnmsumm.html

MULTIMEDIA:

Image link for media: https://www.Send2Press.com/300dpi/25-0331-s2p-nrpainmod-300dpi.jpg

NEWS SOURCE: Neurotech Reports

To view the original story, visit: https://www.send2press.com/wire/pain-neuromodulation-market-to-reach-6-5-billion-by-2030/

Biogen VP to Keynote 2025 Bioelectronic Medicine Forum in NYC

NEW YORK, N.Y., March 17, 2025 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that the Eighth Annual Bioelectronic Medicine Forum will take place on April 10, 2025. The one-day event will be held at the New York Academy of Medicine in Manhattan.

Image caption: Medtech and pharmaceutical industry executive Lisa Shafer, Ph.D., will keynote the 2025 Bioelectronic Medicine Forum in New York City on April 10.

Lisa Shafer, a vice president at biotech firm Biogen, will keynote the conference. Shafer has held executive management positions at key pharmaceutical firms such as Teva as well as neurotech firms such as Medtronic. In her distinguished career, she has helped bridge the gap between device and drug therapies as a chief scientific officer and product development executive. She earned her Ph.D. in neuroscience and neuroimmunology from Loyola University.

German firm Precisis, OSA startup LunOSA, European neuroprosthetics firm ReVision, and focused ultrasound firm Sanmai will present for the first time at the meeting. Also presenting will be executives from NeuroSigma, ANEUVO, and Synergia Medical. Venture capital professionals Jeff Chu from Features Capital, Mir Imran from InCube Ventures, and Jeffrey Scott Cohen from Ladenburg Thalmann & Co will participate in a session moderated by JoJo Platt devoted to investment in bioelectronic medicine.

Contributing editor Victor Pikov will moderate a session with executives from three firms in the neuromodulation space for treating obstructive sleep apnea, including market leader Inspire Medical Systems, and challengers Nyxoah and LivaNova.

There will also be several informative panel discussions on key topics such as investment, emerging technologies, and reimbursement. Neurotech Reports editors James Cavuoto, Jeremy Koff, and JoJo Platt will moderate sessions at the event.

Also at the event, former Axonics CEO Ray Cohen will sit down for a fireside chat with Neurotech Reports Senior Consulting Editor Jeremy Koff for a discussion on the bowel and bladder neuromodulation market.

Cirtec Medical is the Platinum Sponsor of the conference. MST is the Gold Sponsor. Osypka and Black Swan IP are Bronze Sponsors.

“Bioelectronic medicine merges some of the best attributes of biopharma and neurotech approaches to treating systemic disorders,” said James Cavuoto, editor and publisher at Neurotech Reports. “This eighth-annual conference will be a key meeting place for entrepreneurs and executives helping to build this industry.”

For more information on the 2025 Bioelectronic Medicine Forum, contact Neurotech Reports at 415 546 1259 or visit this link: http://neurotechreports.com/pages/bioelectronic-medicine-forum.html.

IMAGE link for media: https://www.Send2Press.com/300dpi/25-0317-s2p-LisaShafer-300dpi.jpg

Image caption: Medtech and pharmaceutical industry executive Lisa Shafer, Ph.D., will keynote the 2025 Bioelectronic Medicine Forum in New York City on April 10.

NEWS SOURCE: Neurotech Reports

To view the original story, visit: https://www.send2press.com/wire/biogen-vp-to-keynote-2025-bioelectronic-medicine-forum-in-nyc/

Neurotech Reports Announces First European Leaders Forum

SAN FRANCISCO, Calif., Jan. 30, 2025 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the longest-serving publishing and market intelligence firm covering the neuromodulation industry, announced the launch of its first European management and investment conference. The two-day event, called Neurotech Leaders Forum at imec, will take place on June 3-4, 2025 on the campus of imec in Leuven, Belgium. Imec, a world-leading research and innovation center in nanoelectronics and digital technologies, is deeply committed to advancing health innovations through the power of semiconductor technologies, making it the ideal host for the conference.

Image caption: Tim Denison will keynote the first European Neurotech Leaders Forum on June 3-4, 2025 at imec in Leuven, Belgium.

Tim Denison, Ph.D. FREng, co-founder of Amber Therapeutics, will keynote the conference. Denison also holds a joint appointment in engineering science and clinical neurosciences at Oxford University, where he explores the fundamentals of physiologic closed-loop systems. Prior to that, he was a technical fellow at Medtronic plc and vice president of research & core technology for the Restorative Therapies Group, where he helped oversee the design of next generation neural interface and algorithm technologies for the treatment of chronic neurological disease.

At the conference, Neurotech Reports editor James Cavuoto will offer an update on the state of the European neuromodulation industry. Neurotech Reports editors JoJo Platt, Jeremy Koff, and Victor Pikov will moderate sessions devoted to peripheral nerve stimulation, bioelectronic medicine applications, venture capital investment, and regulatory and reimbursement issues affecting neurotech startups and emerging firms. Imec executives Peter Peumans, Paru Deshpande, and Barun Dutta (who conceived of, and led the Neuropixels program at imec since its inception) will also offer updates on technology advances at the European research and innovation center.

Executives from several emerging neurotechnology startups, including Italian firm WISE srl and German firm Precisis, will also present at the conference during multiple entrepreneur panels. In addition to imec, sponsors of the conference include Cirtec Medical, MST, Valtronic, and Osypka.

Neurotech Reports will also produce the 8th Annual Bioelectronic Medicine Forum on April 10, 2025 in New York City, and the 25th Annual Neurotech Leaders Forum San Francisco, on November 5-6, 2025.

For more information, contact Neurotech Reports at 415 546 1259 or visit: https://neurotechreports.com/pages/leadersforum-europe.html.

MULTIMEDIA:

Image link for media: https://www.Send2Press.com/300dpi/25-0130-s2p-ntrep-timdenison-300dpi.jpg

Image caption: Tim Denison will keynote the first European Neurotech Leaders Forum on June 3-4, 2025 at imec in Leuven, Belgium.

NEWS SOURCE: Neurotech Reports

To view the original story, visit: https://www.send2press.com/wire/neurotech-reports-announces-first-european-leaders-forum/

Tom Oxley to Keynote the 2024 Bioelectronic Medicine Forum in New York City

NEW YORK, N.Y. /ScoopCloud/ -- Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that the Seventh Annual Bioelectronic Medicine Forum will take place on April 5, 2024. The one-day event will be held at the New York Academy of Medicine in Manhattan.

The keynote speaker at this year's event is Tom Oxley, CEO of Synchron and an interventional neurologist at Mount Sinai Health System. Synchron's internationally acclaimed stentrode device can record brain activity from within a blood vessel. In the intended application of the technology, the user's thoughts are captured, decoded and passed wirelessly through the skin to enable control of digital devices that enable movement and speech restoration to previously paralyzed patients.

Executives and entrepreneurs from several early stage and startup bioelectronic medicine firms will make presentations at the conference. Among these are Sinaptica Therapeutics, Neurosoft Bioelectronics, Helius Medical, PathMaker Neurosystems, Five Liters, Nia Therapeutics, Backstop Neural, WISE srl, and NeuroSigma.

There will also be several informative panel discussions on key topics such as investment, emerging technologies, and reimbursement. Neurotech Reports editors James Cavuoto, Jeremy Koff, JoJo Platt, and Victor Pikov will moderate sessions at the event. A panel on investment will feature Diana Saraceni, General Partner at Panakes Partners, David Neustaedter, Venture Partner at Deerfield, and others.

Cirtec Medical is the Platinum Sponsor of the conference. MCRA is the Silver Sponsor and CorTec is the Bronze Sponsor.

"Bioelectronic medicine is one of the most promising new segments of the healthcare industry," said James Cavuoto, editor and publisher at Neurotech Reports. "This seventh-annual conference will be a key meeting place for entrepreneurs and executives helping to build this industry."

For more information on the 2024 Bioelectronic Medicine Forum, contact Neurotech Reports at 415 546 1259 or visit this link: http://neurotechreports.com/pages/bioelectronic-medicine-forum.html.

RELATED LINKS:
https://www.synchron.com/
https://cirtecmed.com/
https://www.mcra.com/
https://www.cortec-neuro.com/

Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that the Seventh Annual Bioelectronic Medicine Forum will take place on April 5, 2024. The one-day event will be held at the New York Academy of Medicine in Manhattan.

Related link: https://www.neurotechreports.com/

Divergent CRO Announces Launch of New Contract Research Organization

ATLANTA, Ga. /ScoopCloud/ -- Divergent CRO, a leading provider of clinical services to biotech and device companies, is pleased to announce the official launch of its new Contract Research Organization (CRO). This new venture aims to revolutionize the research and development process by offering comprehensive and tailored clinical services to meet the unique needs of the biotech and device industries.

With an unwavering commitment to excellence, Divergent CRO provides a wide range of services, including clinical trial management, regulatory affairs, data management, biostatistics, and medical writing. By leveraging our extensive expertise, we are dedicated to helping our clients accelerate the development of innovative biopharmaceuticals and medical devices.

Our team of highly skilled professionals, including experienced clinical researchers, project managers, and regulatory specialists, is dedicated to delivering the highest standards of quality and efficiency throughout each stage of the clinical trial process. We understand the challenges faced by biotech and device companies and are committed to providing flexible and cost-effective solutions to meet their specific needs.

Divergent CRO is equipped with cutting-edge technology and infrastructure to ensure the smooth execution of clinical trials. Our advanced data management systems and secure facilities ensure the confidentiality and integrity of study data, while our robust quality assurance processes guarantee compliance with regulatory requirements.

"We are thrilled to launch our new Contract Research Organization and partner with biotech and device companies to advance the development of life-changing therapies," said Divergent CRO's Owner-Partners. "Our team is dedicated to delivering exceptional results and providing the highest level of service to our clients. With our expertise and commitment to excellence, we are confident that we can make a significant impact on the success of their clinical programs."

Divergent CRO is now accepting inquiries and is available to discuss collaboration opportunities with biotech and device companies seeking to enhance their clinical research capabilities.

For more information, please visit Divergentcro.com or contact our business development team at Customerservice@divergentcro.com or (888) 342-1447.

About Divergent CRO:

Divergent CRO is a leading provider of clinical services to biotech and device companies. With a focus on innovation and quality, we strive to accelerate the development of life-changing therapies through our comprehensive and tailored clinical services. We thrive on leaving our clients and patients satisfied by improving human health and wellness. Our team of experts is dedicated to delivering exceptional results and providing the highest level of service to our clients. At Divergent CRO, we don't just manage clinical trials; we craft personalized solutions, striving to be the difference by transforming challenges into triumphs in the pursuit of groundbreaking healthcare innovation.

Learn more at: https://divergentcro.com/

Social Links:

LinkedIn Page: https://www.linkedin.com/company/divergentcro/

Instagram: https://www.instagram.com/divergent.cro/

TikTok: https://www.tiktok.com/@divergentcro1

YouTube: https://www.youtube.com/@DivergentCRO

Featured Podcasts:

The Jali Podcast - Melyssa Barrett/DivergentCRO - https://melyssabarrett.com/the-jali-podcast/

Episode Thirty-one - AMY HUTTO, PRODUCTIVITY COACH - https://amyhutto.com/podcast/s1ep30

Divergent CRO, a leading provider of clinical services to biotech and device companies, is pleased to announce the official launch of its new Contract Research Organization (CRO). This new venture aims to revolutionize the research and development process by offering comprehensive and tailored clinical services to meet the unique needs of the biotech and device industries.

Related link: https://divergentcro.com/

BioAustinCTX Adds Cindy WalkerPeach and Ryan Hawkins to the Board of Directors

AUSTIN, Texas /ScoopCloud/ -- BioAustinCTX, Central Texas' Life Science industry organization, announced today the appointment of Cindy WalkerPeach, PhD and Ryan Hawkins to its Board of Directors.

Cindy WalkerPeach has been involved in the Central Texas life science ecosystem since 1996, having relocated to Austin to join a bioscience startup. She currently leads the development of the Nexxus Project at the University of Texas at Austin and serves on the national faculty for the National Institutes of Health (NIH) and National Science Foundation (NSF) Innovation Corps (I-Corps) Programs. Prior to UT, she was the Chief Product Development Officer at the Cancer Prevention & Research Institute of Texas (CPRIT). Prior to government service, Dr. WalkerPeach has 20+ years experience in the biotechnology sector as a member of several life science company management teams, all located in Central Texas, where she led product development and commercial operations.

"It's an exciting time, as Central Texas continues its development into a first-class life sciences hub. BioAustinCTX has been, and continues to be, a critical component for connectivity within the region," said WalkerPeach.

Ryan Hawkins is an accomplished biopharmaceutical leader with 25 years' experience in the life sciences. Ryan serves as the Chief Operating Officer at Disruption Labs, a plant-derived delivery technology company serving the nutraceutical industry. Prior to joining Disruption Labs, Ryan was responsible for Technical Operations at Molecular Templates, a clinical stage biotechnology company and spent 20 years in the biopharmaceutical contract development and manufacturing industry.

"All of the ingredients are present in Austin and Central Texas to have thriving, dynamic life science community that creates benefits beyond the advertised value proposition. Being a part of creating our secret sauce recipe that attracts people, conversation, companies, and community building is very exciting. As a member of the BioAustinCTX board, I look forward to unlocking our community's potential in this regard," said Hawkins.

"Cindy and Ryan bring tremendous experience and knowledge and we look forward to the energy and expertise they will bring to advancing BioAustinCTX's pivotal role in growing the life science ecosystem in Central Texas," said Scott Collins, Board of Directors President.

About BioAustinCTX:

BioAustinCTX is a nonprofit organization based in Austin, Texas focused on advancing the life science industry in the Central Texas Region. Visit BioAustinCTX for more information: https://bioaustinctx.com/.

BioAustinCTX, Central Texas' Life Science industry organization, announced today the appointment of Cindy WalkerPeach, PhD and Ryan Hawkins to its Board of Directors. BioAustinCTX is a nonprofit organization based in Austin, Texas focused on advancing the life science industry in the Central Texas Region.

Related link: https://bioaustinctx.com/

Emerging Neurotechnology Startups to Present at 2023 Neurotech Leaders Forum in San Francisco

SAN FRANCISCO, Calif. /ScoopCloud/ -- Neurotech Reports, the publisher of the Neurotech Business Report newsletter, announced that several promising neurotechnology startups and early-stage firms will present at the 2023 Neurotech Leaders Forum in San Francisco, November 6-7. The 23rd annual event-the most established in the industry-will also feature presentations and panel discussions on important issues confronting the neurotechnology industry.

Among the new and emerging neurotech firms presenting at the conference are Opto Biosystems, a U.K. developer of novel diagnostics for brain cancer, NeuraLace Medical, a San Diego-based manufacturer of noninvasive therapies for treating chronic pain, Spark Biomedical, a Texas firm developing noninvasive therapies for treating addiction, and Harmonic Pain Solutions, an Atlanta, GA-area developer of wearable pain devices that use mechanical stimulation.

Jim Schuermann, president and CEO of Saluda Medical, will deliver the keynote address on the morning of November 6. He will speak on the topic "New Directions in Neuromodulation."

Daniel Kraft, founder of NextMed Health, chair of medicine for Singularity University, and chair of the XPrize Pandemic & Health Alliance, will deliver a keynote address on November 7 devoted to the topic, "The Future of Health and Medicine: Where Can Technology Take Us?" Kraft is board certified in internal medicine and pediatrics and completed fellowships in hematology/oncology and bone marrow transplantation at Stanford. He has given six TED & TEDMED talks.

Another featured presenter will be Prasad Shirvalkar, an associate professor at UC San Francisco School of Medicine, who recently co-authored a seminal paper relating to pain biomarkers. Chris Rozell, a professor at Georgia Tech, who recently coauthored a paper on biomarkers for depression, will also make a presentation at the event.

Neurotech Reports senior contributing editor JoJo Platt will moderate a panel titled "Neurotech Investment: Bouncing Back from the Downturn," which will feature advice and recommendations from several venture capital professionals, including Sara Shnider from Joy Ventures, Martin Dieck from Neurotechnology Investors, and Suraj Mudichintala from Action Potential Venture Capital.

Neurotech Reports senior consulting editor Jeremy Koff will moderate a session titled "Changing Landscape: New SCS and PNS Vendors Enter the Scene," which will examine the current competitive environment in neuromodulation. Neurotech Reports editor James Cavuoto will moderate a session titled "Interpreting the Data: Neuromodulation Vendors Ward Off Negative Publications. And Neurotech Reports contributing editor Victor Pikov will moderate a session titled "Choosing Our Role Models: What Neurotech Can Learn from Other Healthcare Industries."

The Platinum Sponsor at this year's event is Cirtec Medical. Micro Systems Technology is the Gold Sponsor. Valtronic, Velentium, Focus, Neo-Bionica, and Iris Biomedical are Silver Sponsors, while TTP and Microdul are Bronze sponsors.

For more information on attending or sponsoring, contact Neurotech Reports at 415 546 1259 or visit this link: https://neurotechreports.com/pages/leadersforum.html

Neurotech Reports, the publisher of the Neurotech Business Report newsletter, announced that several promising neurotechnology startups and early-stage firms will present at the 2023 Neurotech Leaders Forum in San Francisco, November 6-7. The 23rd annual event-the most established in the industry-will also feature presentations and panel discussions on important issues confronting the neurotechnology industry.

Related link: https://www.neurotechreports.com/

Neo-Bionica Appoints Uli Gommel As Chief Technology Officer

LOS ANGELES, Calif. /ScoopCloud/ -- Neo-Bionica, a leading innovator in the field of medical device development and manufacturing, is thrilled to announce the appointment of Uli Gommel as its new Chief Technology Officer (CTO). Uli will lead Neo-Bionica's technology division spearheading its mission to revolutionize the way that companies bring novel neurotechnologies and smart MedTech devices to market.

Uli Gommel joins Neo-Bionica as a global leader in medical engineering with two decades experience spanning Europe, Asia and the US. Prior to joining Neo-Bionica, he was the Director of Mechanical Engineering at Advanced Bionics. There he led the end-to-end development and launch of the HiResTM Ultra 3D Cochelar Implant, a groundbreaking device which won the MedTech Breakthrough Award in 2019 for best overall medical device solution. Uli's expertise also extends to the development of pediatric cochlear implants, specialized surgical tools and high-resolution implantable electrode arrays.

Based in the US and with a proven track record in growing global MedTech teams, Uli's appointment demonstrates Neo-Bionica's commitment to growing its US presence. As CTO of Neo-Bionica, Uli will oversee design, development, and manufacturing services, providing expert insights for clients developing next-generation neurotech and smart MedTech devices. Through an outstanding depth and breadth of bioengineering expertise, fabrication skills, and regulatory know-how, Uli's experience will help to accelerate the development of implantable and wearable neurotechnologies and bioelectronics devices.

"Neo-Bionica is pushing the boundaries of what is possible in the field of neurotechnology," said Uli. "I am honored to join this talented team and contribute to our shared vision of enhancing the lives of the people who will benefit from these products."

Neo-Bionica's CEO, Dr. Ludovic Labat, said "Not only does Uli's expertise and vision align perfectly with our mission to help companies realize the promise of bioelectric devices, but his presence in the US also signals our commitment to serving the needs of this significant market. With his leadership, Neo-Bionica will continue to grow quickly and smartly."

Uli will be leading a team of highly experienced industry and academic professionals with backgrounds in MedTech, mechanical and electronic engineering and previous experience from top-tier institutions including Invetech, Medtronic, Cochlear, Bionics Institute and Planet Innovation.

Neo-Bionica was established in 2021 to meet a need in the Australian market. Despite Australia's deep expertise in the development of advanced MedTech and Neurotech devices, emerging Australian Neurotech innovators were frequently forced to go overseas to prototype and manufacture their devices. Neo-Bionica was established to meet this gap in the market and since its establishment, its expertise and services have been in high demand from not only local innovators but international clients. Given this demand, Neo-Bionica fast-tracked its plan to establish a permanent foothold in the US with Uli's appointment.

About Neo-Bionica:

Neo-Bionica is an advanced Medtech manufacturer that specializes in providing commercialization and manufacturing services to develop digitally-enabled bionic and smart, neurotech medical device innovations. Neo-Bionica's expertise includes developing AI-powered devices designed to restore human function and smart sensors capable of intelligently monitoring human physiology.

Headquartered in Melbourne, Australia, Neo-Bionica has quickly gained recognition within the industry. Neo-Bionica is proud to be empowering the next generation of MedTech innovators with advanced manufacturing services. https://neo-bionica.com/

Neo-Bionica, a leading innovator in the field of medical device development and manufacturing, is thrilled to announce the appointment of Uli Gommel as its new Chief Technology Officer (CTO). Uli will lead Neo-Bionica's technology division spearheading its mission to revolutionize the way that companies bring novel neurotechnologies and smart MedTech devices to market.

Related link: https://neo-bionica.com/

Award-winning universal vaccine method calls for deeper scientific exploration – The Slammer Method

CHESAPEAKE, Va. /ScoopCloud/ -- A new universal vaccine method developed by Eric Kikkert is outlined in an article he wrote called: "The Slammer Method: How to create effective vaccines." It recently appeared in the "Journal of Infectious Diseases and Therapy" and is proposed to work in not just humans, but animals too. The material was presented at the 2023 12th International Conference for Tropical Medicine and Infectious Disease in London, received an award and established as a universal method to create effective vaccines.

As the name denotes, The Slammer Method, quite literally places the organism into "The Slammer" and crushes it through powerful force. The method entails using a series of approaches to dismantle the organism and prepare it for the body's immune system.

It's a new and inspirational method which uses the concepts of physics, biologics and natural extremes to combat an ever-changing environment of infectious diseases.

While the method is rudimentary in design, it's through its simplicity that great things are achievable. It all starts with a container that's capable of withstanding vast amounts of pressure and then subjecting an organism to multiple tests. In turn, these tests will determine how to proceed should the organism cease to function with pressure alone. After that, the next steps can happen which include adding the chemical equivalent of the enzyme or MPO used by the white blood cell to break down the organism.

Medical research will be able to verify that the organism is unable to feed or reproduce and The Slammer Method can be used for all infectious diseases, including HIV. It's derived from several factors in nature and has untapped possibilities.

"The potential to save countless lives is very real," Kikkert says. "It should be seriously explored through modern science, medical research and technological engineering."

Read the complete article: https://www.hilarispublisher.com/open-access/how-to-create-effective-vaccines-93437.html

View the transcript of the presentation in London: https://www.allforyou2020.org/post/how-to-create-effective-vaccines

About Eric Kikkert:

Eric Kikkert has expertise in mechanical engineering and physics. He has a deep understanding of quantum relativity, quantum structures and mechanics and has produced advanced mathematical methods and concepts to create new formulas which permit unification of physics and relativity. It's here that he commits his understandings to biology to reverse engineer the quantum structure with particle physics.

MEDIA CONTACT:
Eric Kikkert, +1-757-949-8864, email: KikkertEric[at]icloud.com

A new universal vaccine method developed by Eric Kikkert is outlined in an article he wrote called: "The Slammer Method: How to create effective vaccines." It recently appeared in the "Journal of Infectious Diseases and Therapy" and is proposed to work in not just humans, but animals too. The material was presented at the 2023 12th International Conference for Tropical Medicine and Infectious Disease in London, received an award and established as a universal method to create effective vaccines.

Helen Mayberg to Keynote 2023 Bioelectronic Medicine Forum in New York City

NEW YORK, N.Y. /ScoopCloud/ -- Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that the Sixth Annual Bioelectronic Medicine Forum will take place on April 4, 2023. The one-day event will be held at the New York Academy of Medicine in Manhattan.

The keynote speaker at this year's event is Helen Mayberg, Director of the Nash Family Center for Advanced Circuit Therapeutics at Mount Sinai School of Medicine. Mayberg is recognized as one of the pioneers of neuromodulation for treating psychiatric disorders. She will speak on the topic, "Pharmacological therapies simply aren't enough."

Other sessions will cover a range of technologies and indications for bioelectronic medicine, including applications in cardiovascular medicine, inflammation, gastrointestinal disorders, and many other clinical specialties. There will also be several informative panel discussions on key topics such as investment, emerging technologies, and reimbursement. Neurotech Reports editors James Cavuoto, Jeremy Koff, JoJo Platt, and Victor Pikov will moderate sessions at the event

The founders and CEOs of several promising bioelectronic medicine startups will also present at the conference. Entrepreneur presenters Brad Schmidt, CEO of Panaxium, which is developing a new "iontronic" brain interface, Marc Powell, CEO of Reach Neuro, which has developed a new stroke rehabilitation therapy, Luca Ravagnan, CEO of WISE srl, an Italian firm developing thin, stretchable brain electrodes, and Karen Crow, CEO of NeuroGeneces, which has developed a sleepband that performs brain health assessment using A.I. and EEG data.

Cirtec Medical is the Platinum Sponsor of the conference. MST is the Gold Sponsor and Valtronic and Velentium are Silver Sponsors.

"Bioelectronic medicine is one of the most promising new segments of the healthcare industry," said James Cavuoto, editor and publisher at Neurotech Reports. "This sixth-annual conference will be a key meeting place for entrepreneurs and executives helping to build this industry."

For more information on the 2023 Bioelectronic Medicine Forum, contact Neurotech Reports at 415 546 1259 or visit this link: https://neurotechreports.com/pages/bioelectronic-medicine-forum.html.

Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that the Sixth Annual Bioelectronic Medicine Forum will take place on April 4, 2023. The one-day event will be held at the New York Academy of Medicine in Manhattan.

Related link: https://www.neurotechreports.com/

The BioBuilder Educational Foundation Initiates Plan to Train Bioeconomy Workforce

NEWTON, Mass. /ScoopCloud/ -- The BioBuilder Educational Foundation, Inc. ("BioBuilder"), which has a decade of empowering teachers and schools to bring synthetic biology education to school districts in 47 states, today announced its launch of a strategic planning process designed to grow the bioeconomy workforce at scale in urban, rural, and tribal communities.

This effort represents an expansion of the work BioBuilder has accomplished to date in Eastern Tennessee. BioBuilder spent several years partnering with secondary schools and East Tennessee State University (ETSU). Last year, the University produced a Synthetic Biology Task Force Report that recommended a roadmap to raise awareness of career opportunities available via synthetic biology and the bioeconomy, and to create programs at the University to teach students and ready them for those jobs.

BioBuilder's next phase, in which it will build on the learning from Eastern Tennessee, is to develop a plan to grow the bioeconomy workforce across the USA, while still considering local contexts. The work will be made possible by support from Schmidt Futures, a philanthropic initiative of Eric and Wendy Schmidt that bets early on exceptional people making the world better.

Dr. Natalie Kuldell, founder and Executive Director of BioBuilder, shared, "BioBuilder is committed to inspiring students to learn and love life science, on a path to bright futures, successful careers, and a better world. We're thankful for Schmidt Futures support of our next steps, as we address the bioeconomy's shortage of trained technical talent."

Schmidt Futures is a philanthropic initiative founded by Eric and Wendy Schmidt that bets early on exceptional people making the world better. Through work with partners like BioBuilder, Schmidt Futures aims to bring talented people together in networks to prove out their ideas and solve hard problems in science and society.

Dr. Mary Maxon, Executive Director of the Schmidt Futures BioFutures Pprogram, remarked that "BioBuilder's accessible curriculum has made a substantial impact on secondary and post-secondary life-science education. We look forward to the plan they develop for scaling their early successes and expanding the geographic diversity of biotechnology opportunities."

For more information about The BioBuilder Education Foundation, please contact [info@biobuilder.org] or visit https://biobuilder.org.

About BioBuilder:

Created by an award-winning team from MIT, BioBuilder empowers teachers and schools to better serve students and employers by elevating the skills that students are taught. Founded in 2011, BioBuilder has grown to partner with schools in almost every state and around the world. BioBuilder builds confidence in teachers to learn and apply the synthetic biology curricula, and provides laboratory kits and an openly accessible textbook that enable experiential learning.

BioBuilder also works directly with district and community leaders to identify potential roadblocks to narrow the gap between science innovation and science education - at least for biology - across the U.S., and better match the skill of our nation's workforce to the needs of the synthetic biology industry. Learn more by visiting https://biobuilder.org/.

About Schmidt Futures:

Schmidt Futures bets early on exceptional people making the world better. Founded by Eric and Wendy Schmidt, Schmidt Futures is a philanthropic initiative that brings talented people together in networks to prove out their ideas and solve hard problems in science and society. To learn more about our method and the diverse types of capital and tools that we deploy, visit: https://www.schmidtfutures.com

The BioBuilder Educational Foundation, Inc. ("BioBuilder"), which has a decade of empowering teachers and schools to bring synthetic biology education to school districts in 47 states, today announced its launch of a strategic planning process designed to grow the bioeconomy workforce at scale in urban, rural, and tribal communities.

Related link: https://biobuilder.org/

BioBuilder and K2 Scientific Bring Synthetic Biology Programs and Laboratory Equipment to High-Need High Schools Around the Country

BOSTON, Mass. /ScoopCloud/ -- As a world-recognized program that trains the next generation of innovators and skilled workers in synthetic biology, the BioBuilder Educational Foundation announced new work with K2 Scientific to make high quality tools and equipment for life science research widely accessible. BioBuilder has partnered with K2 Scientific, who will donate industry-grade refrigeration units to four high-need high schools participating in the BioBuilderClub this academic year.

Consistent refrigeration of laboratory reagents is essential for a wide variety of biotechnology experiments and applications. Without precise temperature control and storage, materials and supplies for life science research degrade. Yet many high school educators, especially those in under-resourced school districts, rely on limited and unreliable cold-storage units. Many teachers forgo hands-on laboratory experiments without the appropriate cold storage equipment.

Recognizing that many high schools face financial constraints that limit classroom opportunities in the field of synthetic biology, BioBuilder annually runs the BioBuilderClub program. Since its inception in 2015, more than 1850 students from demographically and geographically diverse schools in 24 states and 7 countries have participated in a total of 202 BioBuilderClubs at low or no cost to the schools themselves. The BioBuilderClub supports real and meaningful student research, enabling high school students to take their ideas from concept to prototype to publication.

On November 9, 2022, staff and leadership from K2 Scientific and BioBuilder identified the first of four BioBuilderClubs to receive a freezer this academic year. The first recipient is the BioBuilderClub team from the Manhattan Comprehensive Night and Day High School (MCNDHS), a public school in New York City that serves students in grades 10-12.

Alfred Lwin, the MCNDHS BioBuilderClub lead teacher, said, "Our refrigerator is 20 years old, and sometimes we have difficulties using its freezer for cold storage. Thanks to the generous donation of a lab grade refrigerator by K2 Scientific, we will be able to use cold storage for our BioBuilder and other biotechnology labs."

Dee Jetton, COO from K2 Scientific, shared, "We could not be prouder to support this program. I am always so excited to see the great things the BioBuilder Program and its participants are accomplishing. We are thrilled to contribute to BioBuilder programs around the country. K2 Scientific is committed to equity and inclusion, so bringing medical and laboratory grade equipment to high-need schools is a perfect mission fit. It's nice for our team to learn about students' aha moments and accomplishments resulting from K2's support of young scientists in the field."

Founder and Executive Director of BioBuilder, Dr. Natalie Kuldell noted, "Our BioBuilderClubs are often the first - and sometimes the only - time high school students can engage in authentic research before they launch into college or careers. By making that research experience more accessible and more meaningful, we can effectively engage the next generation of scientific innovators and productively prepare our future citizens."

About BioBuilder:

Created by an award-winning team from MIT, BioBuilder empowers teachers and schools to better serve students and employers by elevating the skills that students are taught. Founded in 2011, BioBuilder has grown to partner with schools in almost every state and around the world. BioBuilder builds confidence in teachers to learn and apply the synthetic biology curricula, and provides laboratory kits and an openly accessible textbook that enable experiential learning.

BioBuilder also works directly with district and community leaders to identify potential roadblocks to narrow the gap between science innovation and science education - at least for biology - across the U.S., and better match the skill of our nation's workforce to the needs of the synthetic biology industry. Learn more by visiting https://biobuilder.org/.

About K2 Scientific:

K2 Scientific provides high-performance, medical, cold storage solutions at value prices, offering an extensive line serving US Life Science corporations and North and South American distributors. All K2 orders ship from the North Carolina basecamp. For more information, visit https://k2sci.com and follow us on LinkedIn, Instagram @K2_Scientific

As a world-recognized program that trains the next generation of innovators and skilled workers in synthetic biology, the BioBuilder Educational Foundation announced new work with K2 Scientific to make high quality tools and equipment for life science research widely accessible. BioBuilder has partnered with K2 Scientific, who will donate industry-grade refrigeration units to four high-need high schools participating in the BioBuilderClub this academic year.

Related link: https://biobuilder.org/

Dosaggio™ by SottoPelle® Partners with PatientNow

SCOTTSDALE, Ariz. /ScoopCloud/ -- Dosaggio™ by SottoPelle® and PatientNow announced today that they have entered into a partnership that integrates the two companies' innovative technologies, to improve efficiencies and elevate patient care for providers offering bioidentical hormone replacement therapy (BHRT).

This collaboration offers medical providers a powerful and seamless integration of capabilities for bioidentical hormone replacement therapy practices.

This partnership brings together PatientNow's robust functional EHR with the advanced and powerful Dosaggio™ hormone dosing tool, enabling medical providers to expand their functional medicine practices into the bioidentical hormone therapy arena.

PatientNow is a functional, full-service EHR that offers customized and integrated scheduling, charting, billing, reporting, prescription management, and treatment plan solutions for medical practices. The PatientNow EHR offers flexibility for each provider's needs - all with fair pricing.

The Dosaggio™ bioidentical hormone pellet therapy dosing application allows medical providers to optimize their patient's hormone health through precise, individualized hormone dosing. Dosaggio™ by SottoPelle® offers providers a proprietary online hormone dosing calculator that uses the patient's unique health data to calculate a precise, individualized BHRT dose. Dosaggio™ combines a powerful algorithm with on-screen clinical guidance that enables medical providers to approach each patient's hormone health care in an individualized manner.

The integration of these two platforms allows medical providers to pull patient data such as lab work, demographics, past hormone therapy notes, and other documentation from their PatientNow EHR into the Dosaggio™ dosing application. This eliminates the need for double documentation and helps seamlessly maintain continuity of care for BHRT patients.

"The Dosaggio and PatientNow integration will help providers bring quality care to their patients who suffer from hormonal imbalance," stated CarolAnn Tutera, CEO of Dosaggio™ by SottoPelle®. "It is our mission to help providers bring individualized care to more patients, to help them age gracefully."

Practices that are currently using PatientNow's EHR can conveniently set up their Dosaggio™ account by visiting the integrations page within their account. Medical providers who are interested in learning more about this exciting integration may visit: https://sottopelle.health.

Dosaggio™ by SottoPelle® and PatientNow announced today that they have entered into a partnership that integrates the two companies' innovative technologies, to improve efficiencies and elevate patient care for providers offering bioidentical hormone replacement therapy (BHRT).

Related link: https://www.sottopelletherapy.com/

Dosaggio by SottoPelle Partners with Cerbo

SCOTTSDALE, Ariz. /ScoopCloud/ -- Dosaggio™ by SottoPelle® and Cerbo announced today that they have entered into a partnership that integrates the two companies' innovative technologies, to improve efficiencies and elevate patient care for providers offering bioidentical hormone replacement therapy (BHRT).

Dosaggio™, the original, multi-patented hormone therapy dosing platform for physicians, announces its exciting new partnership with Cerbo electronic health records (EMR). This collaboration offers medical providers a powerful and seamless integration of capabilities for bioidentical hormone replacement therapy practices.

This partnership brings together Cerbo's robust functional EHR with the advanced and powerful Dosaggio™ hormone dosing tool, enabling medical providers to expand their functional medicine practices into the bioidentical hormone therapy arena.

Cerbo is a functional, full-service EHR that offers customized and integrated scheduling, charting, billing, reporting, prescription management, and treatment plan solutions for medical practices. The Cerbo EHR offers flexibility for each provider's needs - all with fair pricing.

The Dosaggio™ bioidentical hormone pellet therapy dosing application allows medical providers to optimize their patient's hormone health through precise, individualized hormone dosing. Dosaggio™ by SottoPelle® offers providers a proprietary online hormone dosing calculator that uses the patient's unique health data to calculate a precise, individualized BHRT dose. Dosaggio™ combines a powerful algorithm with on-screen clinical guidance that enables medical providers to approach each patient's hormone health care in an individualized manner.

The integration of these two platforms allows medical providers to pull patient data such as lab work, demographics, past hormone therapy notes, and other documentation from their Cerbo EHR into the Dosaggio™ dosing application. This eliminates the need for double documentation and helps seamlessly maintain continuity of care for BHRT patients.

"The Dosaggio and Cerbo integration will help providers bring quality care to their patients who suffer from hormonal imbalance," stated CarolAnn Tutera, CEO of Dosaggio™ by SottoPelle®. "It is our mission to help providers bring individualized care to more patients, to help them age gracefully."

Practices that are currently using Cerbo's EHR can conveniently set up their Dosaggio™ account by visiting the integrations page within their account.

Medical providers who are interested in learning more about this exciting integration may visit: https://sottopelle.health.

Learn more about SottoPelle® Therapy at: https://www.sottopelletherapy.com/.

Dosaggio™ by SottoPelle® and Cerbo announced today that they have entered into a partnership that integrates the two companies' innovative technologies, to improve efficiencies and elevate patient care for providers offering bioidentical hormone replacement therapy (BHRT).

Related link: https://www.sottopelletherapy.com/

BioBuilder funded to expand student opportunity in rural and urban areas through its collaborative after school program

BOSTON, Mass. /ScoopCloud/ -- Thanks to a two-year grant recently awarded by BioMADE, the BioBuilder Educational Foundation will expand a program that has supported thousands of high school inventors over the last decade. BioBuilder is leading the project, "Launching High School Bioengineers on their Paths to College and Careers," with funding that will bring the authentic tools and approaches for engineering biology to BioBuilderClub students nationwide in collaboration with East Tennessee State University, Ars Biotechnica, and Daicel Arbor Biosciences.

Support from BioMADE will enable these organizations to provide teams of young innovators new opportunities to design, build and test their biodesigns, and submit their research for publication as peer-reviewed manuscripts in BioTreks (Ars Biotechnica). Industry-standard biomanufacturing reagents and mentorship from professional scientists will be provided by Daicel Arbor, while East Tennessee State University will expand the geographic and demographic reach of the BioBuilderClub and spearhead a rigorous evaluation of its impact.

Thomas Tubon, Chief Workforce Development Officer for BioMADE said, "With the bioeconomy expected to contribute over a million jobs in this field by 2030, and the growing desire to connect local feedstocks to nearby manufacturing capabilities, a program like this is essential as it can raise awareness and provide opportunities to students, regardless of geography or demography."

Founder and Executive Director of BioBuilder, Dr. Natalie Kuldell shared that, "We are thrilled to be building momentum in non-traditional STEM hubs. By simultaneously training students and celebrating their achievements, this work will draw students into the exciting and creative sides of science and engineering. It will also increase awareness among community stakeholders, including parents of participating students, high school teachers, college admissions officers, and relevant local businesses."

These goals are fully aligned with the recently signed Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy that establishes the National Biotechnology and Biomanufacturing Initiative. The National Biotechnology and Biomanufacturing Initiative will create jobs, leverage biotechnology to build more resilient supply chains, improve health outcomes, and lower prices for Americans by expanding biomanufacturing capacity, creating market pathways for bio-based products, training a diverse workforce, and fostering innovation.

About BioBuilder:

Created by an award-winning team from MIT, BioBuilder empowers teachers and schools to better serve students and employers by elevating the skills that students are taught. Founded in 2011, BioBuilder has grown to partner with schools in almost every state and around the world. BioBuilder builds confidence in teachers to learn and apply the synthetic biology curricula, and provides laboratory kits and an openly accessible textbook that enable experiential learning.

BioBuilder also works directly with district and community leaders to identify potential roadblocks to narrow the gap between science innovation and science education -- at least for biology - across the U.S., and better match the skill of our nation's workforce to the needs of the synthetic biology industry. Learn more by visiting https://biobuilder.org/.

About BioMADE:

Launched in 2021, BioMADE is a Manufacturing Innovation Institute sponsored by the U.S. Department of Defense. By supporting the development of biomanufacturing technologies, BioMADE and its network of 150+ members across 29 states are strengthening American competitiveness, creating a more resilient supply chain, and helping the U.S. becoming more self-sufficient. Learn more about BioMADE by visiting https://www.biomade.org/.

About ETSU:

East Tennessee State University (ETSU) is a public research university in Johnson City, Tennessee. It is the fourth largest university in the state with nearby off-campus centers. It hosts the James H. Quillen College of Medicine, often ranked as one of the top schools in the United States for rural medicine and primary care education; the Bill Gatton College of Pharmacy, the College of Nursing, the College of Public Health, and the recently formed College of Clinical and Rehabilitative Health Sciences. Learn more about ETSU at https://www.etsu.edu/.

About Ars Biotechnica:

Ars Biotechnica is a public nonprofit corporation with the goal of teaching high school students and teachers about synthetic biology. They publish BioTreks, the first international synthetic biology journal to be authored and reviewed by high school students. The journal is intended to give participating students the valuable experiences of writing and evaluating scientific papers, while offering them opportunities to share their own synthetic biology ideas, techniques, and results in a professionally edited, online publication. Learn more by visiting https://biotreks.org/.

About Daicel Arbor Biosciences:

Daicel Arbor Biosciences, a subsidiary of Chiral Technologies, Inc. (part of Daicel Corporation), is a biotech company that is specialized in targeted Next Generation Sequencing (NGS), in situ hybridization probe design, and cell-free protein expression. Their products and services have been utilized in broad applications in genomics, cytogenetics, and synthetic biology. They have served customers in plant, animal, human, bacteria, and virus areas for more than fifteen years. Learn more by visiting https://arborbiosci.com/.

Thanks to a two-year grant recently awarded by BioMADE, the BioBuilder Educational Foundation will expand a program that has supported thousands of high school inventors over the last decade. BioBuilder is leading the project, "Launching High School Bioengineers on their Paths to College and Careers," with funding that will bring the authentic tools and approaches for engineering biology to BioBuilderClub students nationwide in collaboration with East Tennessee State University, Ars Biotechnica, and Daicel Arbor Biosciences.

Related link: https://biobuilder.org/

Kalyagen Announces Attendance and Speaking Engagement at 8th Annual Biohacking Conference

AUSTIN, Texas /ScoopCloud/ -- Kalyagen is pleased to announce that it will be attending and its founder, Christian Drapeau, will be speaking at the upcoming 8th Annual Biohacking Conference. The conference, which is completely sold out, will be held September 15-17 at The Beverly Hilton in Beverly Hills, California.

"The Biohacking Conference will be an ideal opportunity to introduce STEMREGEN directly to an audience whose core focus is to tap into the body's innate ability to repair," said Christian Drapeau. "We are eager to meet and collaborate with the leaders of the biohacking movement."

STEMREGEN® is a unique and patent-pending blend of proprietary plant-based extracts documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM). Ingredients in STEMREGEN® have been investigated in more than eight studies for their effect on stem cell function, of which five were randomized, double-blind, placebo-controlled human clinical trials. STEMREGEN® has wide application in anti-aging and overall health maintenance.

"The link between a lower number of circulating stem cells and the development of age-related diseases has been well studied with numerous degenerative conditions, including diabetes, cardiovascular diseases, atherosclerosis, Alzheimer's disease, rheumatoid arthritis, pulmonary diseases, erectile dysfunction, and kidney disease," continued Mr. Drapeau. "From a therapeutic standpoint, increasing the number of circulating stem cells has been documented to enhance tissue repair or improve the course of disease formation in many degenerative conditions and overall health and well-being."

About Kalyagen:

Austin-based Kalyagen® was founded by Christian Drapeau, author of the bestseller Cracking the Stem Cell Code. Kalyagen® is a leader in the research and development of natural products aimed at supporting stem cell function of the body. Stem cells constitute the natural repair system of the body, and stem cell enhancers have been documented to strongly contribute to improving health and quality of life. STEMREGEN® is the first stem cell enhancer product developed by Kalyagen®. STEMREGEN® is a unique blend of proprietary plant-based extracts documented to support Endogenous Stem Cell Mobilization and provide other health benefits.

For more information, please visit our website: https://www.kalyagen.com/

CONTACT:

Biomics, LLC (dba Kalyagen®)

Herbert Dogan, Chief Marketing Officer (310-433-8072)

hgd@kalyagen.com

Social media: @kalyagen #kalyagen #christiandrapeau #stemcellchristian #stemregen #stemcells #stemregeneffect #stemthetideoftime #stemthetide #biohacking

Disclaimer: None of the statements contained in this press release have been evaluated by the U.S. Food and Drug Administration. The products and information in the release are not intended to diagnose, treat, cure or prevent any disease.

Kalyagen is pleased to announce that it will be attending and its founder, Christian Drapeau, will be speaking at the upcoming 8th Annual Biohacking Conference. The conference, which is completely sold out, will be held September 15-17 at The Beverly Hilton in Beverly Hills, California.

Related link: https://www.kalyagen.com/

Proteios Technology, Inc. Awarded $1.6 Million NIH SBIR Grant to Commercialize its Multivariate Cell Isolation Technology

SEATTLE, Wash. /ScoopCloud/ -- Proteios Technology, Inc. is pleased to announce it's received a $1.6 million SBIR Phase II grant from the National Institutes of Health (NIH) to commercialize its multivariate (parallel) cell isolation technology. Grant funds will be used to extend Proteios' cell isolation kits to include up to 20 of the most common cell types currently used in cell therapy development.

Cell biology is complex. And conducting experiments on an isolated population of cells, rather than a heterogeneous mix, is a common approach to reduce experimental complexity. Cell isolation allows cell biologists to confidently attribute observed effects and responses to a particular cell type.

Specifically, Proteios' multivariate cell isolation technology provides high-performance, antibody- and magnetic bead-free isolation of cell types in fewer than 30 minutes. This is a big reduction in time compared to currently available methods, while meeting or exceeding cell yield, purity and viability.

Proprietary Proteios Chimeras will be designed and developed to bind to each of the 20 target cell types with high specificity and selectivity through a combination of robotic biological screening, Machine Learning (ML) and Molecular Dynamics (MD) simulation.

Proteios will also incorporate Proteios Chimeras into its cGMP cell therapy manufacturing device - a bench prototype funded under contract by the National Cancer Institute (NCI). The device provides end-to-end manufacturing of cell therapies in a closed and fully-automated system with concise control over the multiple cell types that form the basis of cell therapy formulations. Proteios Chimeras will be a major component of consumables for the cGMP cell therapy manufacturing device.

"It's believed that the effectiveness of cellular therapeutics can be improved by the addition/removal of certain secondary cell types," Bob Snyder, Ph.D., co-founder and CEO of Proteios Technology, says. "Proteios' cell isolation technology will provide for the parallel enrichment and/or depletion of any cell type as new cell therapy formulations are investigated, reducing the vein-to-vein time and overall manufacturing cost."

Proteios is also preparing for the immediate commercial release of its research-scale recombinant protein purification kits which will provide a viable alternative to His Tag technology, unusable with about 20 percent of proteins of interest.

Initially, Proteios will launch two kits based on a proprietary affinity tag and a silica-based resin for:

1 - high-expressing proteins; and

2 - low-expressing proteins.

To learn more: https://www.proteios.com/

About Proteios Technology:

Proteios Technology is a leading provider of products and services dedicated to supporting the discovery of advanced therapeutics and their efficient manufacturing. Its innovative solutions support research at all levels from discovery and translational research to cGMP manufacturing and companion diagnostics. Its technologies enable the multivariate (parallel), tag-free isolation of any biological, including proteins/biopharmaceuticals, cell types, antibodies and viruses. Proteios' research-scale kits enable the discovery of new advanced therapeutics. And the inherent scalability of the technology allows the same methodology to be used in the manufacturing of advanced therapeutics and dramatically reduces the time required for process development.

Proteios is driven by the goal to lower the cost of healthcare and to provide advanced therapeutics to a larger patient population. It's located in the heart of Seattle and adjacent to some of the world's leading cell therapy research institutes - including the Fred Hutchinson Cancer Research Center, Seattle Children's Research Institute and the Seattle Cancer Care Alliance.

Proteios Technology, Inc. is pleased to announce it's received a $1.6 million SBIR Phase II grant from the National Institutes of Health (NIH) to commercialize its multivariate (parallel) cell isolation technology. Grant funds will be used to extend Proteios' cell isolation kits to include up to 20 of the most common cell types currently used in cell therapy development.

Related link: https://www.proteios.com/

Kalyagen Announces Attendance at the Fort Lauderdale Open with PGA Associate Jerrel Gill

AUSTIN, Texas /ScoopCloud/ -- Kalyagen® is pleased to announce that it will be attending the Fort Lauderdale Open as part of its sponsorship of golf professional Jerrel Gill. The Open will be hosted at the Fort Lauderdale Country Club on May 2-3, 2022. Kalyagen is also a supporting partner for two upcoming South Florida PGA Section events, the South Florida PGA Foundation HOPE Classic on May 12, 2022 and the South Florida Open on June 21-23, 2022.

"I'm pleased to introduce Kalyagen to the Fort Lauderdale Open and the South Florida PGA and the PGA Hope program benefiting veterans like myself and some of my team members," said Desmond Dogan, Director of Sales at Kalyagen®. "As a former golf professional and club pro, I understand the grind that is associated with practicing, playing, teaching, running the pro shop and more. That's why I'm pleased that Kalyagen is sponsoring Jerrel Gill, presently a Class B-13 PGA Associate. Jerrel will be playing in both the Fort Lauderdale Open and the Hope Classic and will attempt to qualify for the South Florida Open."

STEMREGEN® is a unique and patent-pending blend of proprietary plant-based extracts documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM). Ingredients in STEMREGEN® have been investigated in more than eight studies for their effect on stem cell function, of which five were randomized, double-blind, placebo-controlled human clinical trials. STEMREGEN® has wide application in antiaging and overall health maintenance.

"Despite my local success, I am determined to improve my game and consistently compete against the best PGA Professionals," said Jerrel Gil, PGA professional golfer. "I have been fortunate enough to partner with Kalyagen and use its stem cell enhancement supplement STEMREGEN to assist me to contend in the South Florida PGA Section and hopefully on the PGA Tour. I've already picked up distance on my drive!"

"We are delighted to partner with Jerrel and the South Florida PGA Section," said Kalyagen® founder and CEO Christian Drapeau. "The link between a lower number of circulating stem cells and the development of age-related diseases and lack of recovery has been well studied. From a therapeutic standpoint, increasing the number of circulating stem cells has been documented to enhance tissue repair and improve the course of disease formation in many degenerative conditions and overall health and well-being. We have already begun to see improvement in Jerrel's training and recovery efforts and look forward to continuing to assist his golf career with the benefits of STEMREGEN on his team."

About Kalyagen:

Austin-based Kalyagen® was founded by Christian Drapeau, author of the bestseller Cracking the Stem Cell Code. Kalyagen® is a leader in the research and development of natural products aimed at supporting stem cell function of the body. Stem cells constitute the natural repair system of the body, and stem cell enhancers have been documented to strongly contribute to improving health and quality of life. STEMREGEN® is the first stem cell enhancer product developed by Kalyagen®. STEMREGEN® is a unique blend of proprietary plant-based extracts documented to support Endogenous Stem Cell Mobilization and provide other health benefits. For more information, please visit our Website: https://www.kalyagen.com/.

About Jerrel Gill:

Jerrel Gill has excelled in various management fields since graduating with honors from Hampton University with a Bachelor's of Science in Business Management. Hampton University is a historic Black college and university in Hampton, Virginia. Mr. Gill reentered the golf industry as a registered PGA Associate in April of 2019 and was quickly promoted to Assistant Golf Professional at Plantation Preserve Golf Course and Club in Plantation, Florida. In March 2020, he was promoted to General Manager of The Bridges at Springtree Golf Club in Sunrise, FL. During the last three years as a PGA Associate, Mr. Gill has quickly made himself known as a competitive golfer in the South Florida PGA Section. His best finish was a tie for 2nd place at the 2021 DEK Classic with an additional five top-15 finishes in the Southern Section in 2021.

About Desmond Dogan:

Following high school and a once-in-a lifetime experience with the USA Jr. National Olympic Hockey Team, Mr. Dogan served as a Navy Corpsman. After a successful five-year stint with the Navy, Mr. Dogan spent the next twelve years as an Operating Room Technician at LA-based Cedar Sinai Medical Center. After graduating from the Orlando Chapter of the Golf Academy of America and passing the PGA playing ability test on his first attempt, Mr. Dogan was offered the Head Professional position at the famed Inverrary Country Club. This led to a Head Professional/ Director of Golf position with the Billy Casper Golf Management group in Chicago. In addition to his current role with Kalyagen®, Mr. Dogan continues to be heavily involved in the not-for-profit world.

CONTACT:

Biomics, LLC (dba Kalyagen®)

Herbert Dogan, Chief Marketing Officer (310-433-8072)

hgd@kalyagen.com

SOCIAL MEDIA:

@kalyagen @southfloridapga #kalyagen #stemregen #stemcells #stemregeneffect #stemthetideoftime #stemthetide #pga #southfloridapga #jerrelgill #fortlauderdaleopen

Disclaimer: None of the statements contained in this press release have been evaluated by the U.S. Food and Drug Administration. The products and information in the release are not intended to diagnose, treat, cure or prevent any disease.

Kalyagen® is pleased to announce that it will be attending the Fort Lauderdale Open as part of its sponsorship of golf professional Jerrel Gill. The Open will be hosted at the Fort Lauderdale Country Club on May 2-3, 2022.

Related link: https://www.kalyagen.com/

Kalyagen Announces Attendance at Paleo f(x) 2022 Conference

AUSTIN, Texas /ScoopCloud/ -- Kalyagen is pleased to announce that it will be attending and hosting a booth (#121) at the upcoming Paleo f(x)™ 2022 conference to be held in Austin on April 29 - May 1.

"We recently attended the SXSW Conference and received a warm welcome from the Austin community," said Christian Drapeau, Kalyagen founder. "Paleo f(x) will be another opportunity to present STEMREGEN to our home-town Austin community at one of the world's premier wellness events."

STEMREGEN® is a unique and patent-pending blend of proprietary plant-based extracts documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM). Ingredients in STEMREGEN® have been investigated in more than eight studies for their effect on stem cell function, of which five were randomized, double-blind, placebo-controlled human clinical trials. STEMREGEN® has wide application in antiaging and overall health maintenance.

"The link between a lower number of circulating stem cells and the development of age-related diseases has been well studied with numerous degenerative conditions, including diabetes, cardiovascular diseases, atherosclerosis, Alzheimer's disease, rheumatoid arthritis, pulmonary diseases, erectile dysfunction, and kidney disease," continued Mr. Drapeau. "From a therapeutic standpoint, increasing the number of circulating stem cells has been documented to enhance tissue repair or improve the course of disease formation in many degenerative conditions and overall health and well-being."

ABOUT KALYAGEN:

Austin-based Kalyagen® was founded by Christian Drapeau, author of the bestseller Cracking the Stem Cell Code. Kalyagen® is a leader in the research and development of natural products aimed at supporting stem cell function of the body. Stem cells constitute the natural repair system of the body, and stem cell enhancers have been documented to strongly contribute to improving health and quality of life. STEMREGEN® is the first stem cell enhancer product developed by Kalyagen®. STEMREGEN® is a unique blend of proprietary plant-based extracts documented to support Endogenous Stem Cell Mobilization and provide other health benefits.

For more information, please visit our Website: https://www.kalyagen.com/

CONTACT:

Biomics, LLC (dba Kalyagen®)

Herbert Dogan, Chief Marketing Officer (310-433-8072)

hgd@kalyagen.com

SOCIAL MEDIA:

@kalyagen #kalyagen #stemregen #stemcells #stemregeneffect #stemthetideoftime #stemthetide #paleofx #wellnessexpo #austin

DISCLAIMER:

None of the statements contained in this press release have been evaluated by the U.S. Food and Drug Administration. The products and information in the release are not intended to diagnose, treat, cure or prevent any disease.

Kalyagen is pleased to announce that it will be attending and hosting a booth (#121) at the upcoming Paleo f(x)™ 2022 conference to be held in Austin on April 29 - May 1. STEMREGEN® is a unique and patent-pending blend of proprietary plant-based extracts documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM).

Related link: https://www.kalyagen.com/

Oral Vaccine Boosts COVID Immunity: study conducted on nonhuman primates is published in the journal Vaccine

ROCHESTER, Minn. /ScoopCloud/ -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced results confirming the activity of an oral vaccine formulation for boosting immunity against SARS-CoV-2. The full study conducted on nonhuman primates is published in the journal Vaccine accessible at http: https://www.sciencedirect.com/science/article/pii/S0264410X21016716

The article describes the evaluation of an oral COVID-19 vaccine built on the vesicular stomatitis virus (VSV) platform. Oral administration of the VSV based vaccine induced antibodies that could neutralize SARS-CoV-2, the virus that causes COVID-19. More importantly, the novel oral formulation powerfully boosted the levels of neutralizing antibodies against SARS-COV-2 in previously vaccinated monkeys. The oral vaccine was shown to be safe and did not cause clinically significant adverse effects.

"By tweaking the way we generate the VSV-SARS vaccine, we created a new oral formulation that worked remarkably well to boost virus neutralizing antibody titers when administered into the cheek pouches of cynomolgus macaques whose immunity was waning after they had been primed with an intramuscular vaccine," stated Kah-Whye Peng, Ph.D., Chief Technical Officer of Vyriad, and first author of this publication. "Oral dosing is convenient and more likely to be accepted by people who are reluctant to receive yet another intramuscular injection to boost their immunity."

The COVID-19 pandemic is not over and there is a continued need to deliver vaccines to a much of the world's population. An effective oral vaccine/booster has the potential to dramatically improve vaccine uptake rates by addressing some of the key barriers to effective deployment such as logistics of distribution to remote populations, fear of needles, and administration to young children.

"We are excited by these groundbreaking findings. Vyriad has cGMP manufacturing capabilities and is running clinical trials using an engineered VSV for cancer therapy. We are therefore actively seeking partnership to help bring this promising platform to human testing," stated Stephen J Russell, M.D., Ph.D., Chief Executive Officer of Vyriad.

The publication is a collaboration between researchers at Vyriad, Imanis Life Sciences, Regeneron Pharmaceuticals, and the University of Minnesota.

About Vyriad, Inc.

Vyriad is a clinical-stage company developing virus-based therapeutics, focusing initially on proprietary oncolytic virus therapies for the treatment of cancers with significant unmet needs. Founded by scientists at Mayo Clinic and the University of Miami, Vyriad is working with VSV, measles and picornavirus platforms, programming their viruses to selectively attack cancer cells, thereby igniting antitumor immune responses that can complete the process of tumor destruction and prevent disease recurrence.

Our lead platform, derived from vesicular stomatitis virus (VSV), is being evaluated in ongoing Phase 1-2 clinical trials addressing multiple cancer types. Vyriad and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have a well-established broad-based strategic agreement for the discovery and development of new oncolytic virus treatments for cancer leveraging Vyriad's VSV platform and Regeneron's PD-1 inhibitor Libtayo® (cemiplimab-rwic) as well as its unmatched antibody discovery capabilities. Vyriad is a privately held company based in Rochester, Minnesota.

For more information, visit https://vyriad.com/.

Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced results confirming the activity of an oral vaccine formulation for boosting immunity against SARS-CoV-2. The full study conducted on nonhuman primates is published in the journal Vaccine.

Related link: https://vyriad.com/

Myrio Therapeutics and Pure MHC, LLC Announce Research Collaboration to Develop Novel, Targeted Antibody-Based Cancer Therapies

OKLAHOMA CITY, Okla. /ScoopCloud/ -- Pure MHC, LLC and Myrio Therapeutics Pty Ltd (Myrio) today announced a collaboration to develop new antibody-based oncology therapeutics. The companies will combine Pure MHC's proprietary offering of MHC peptide targets for oncology with Myrio's revolutionary Retained Display(tm) (ReD) antibody discovery process to initially create up to three novel therapies based on targets distinct to tumors across multiple types of cancer.

The cancer therapies resulting from this collaboration will represent a unique synergism: Myrio's ReD platform is differentiated in its ability to routinely identify antibodies that bind to peptides from intracellular proteins presented on the cell surface by major histocompatibility complex (MHC), and Pure MHC is a world-leader in the identification and validation of peptide/MHC (pMHC) targets. Antibodies to next generation pMHC oncology targets may provide more efficacious therapies, particularly for solid tumors, while minimizing off-target effects for patients.

Researchers at both companies expressed excitement at the prospect of combining these innovative approaches:

"The speed and flexibility of Myrio's ReD platform enables the generation of robust antibody-based therapies against challenging targets like pMHC with high affinity and specificity," said Myrio's CEO Pete Smith. "Pure MHC's curated pMHC targets are an excellent fit for our platform and substantially de-risk downstream development."

Pure MHC's Chief Scientist, William Hildebrand, PhD shared this enthusiasm, "Pure MHC is dedicated to the identification of pMHC complexes distinct to cancer and absent from healthy tissues. Peptide/MHC complexes for several oncology indications have been identified by Pure MHC as present on tumors yet absent from healthy tissue, and we are excited for Myrio to deploy their cutting-edge technology to engineer antibodies that recognize our targets with great specificity."

From a business perspective, these therapeutic candidates will bolster Myrio's existing portfolio of in-house assets while providing Pure MHC access to a powerful antibody platform that enables multiple therapeutic pipelines.

"Myrio's platform is not just an outstanding scientific fit, the collaboration represents a unique and exciting way for Pure MHC to deploy its novel target assets strategically," said Kris Looney, President of Pure MHC. "As we continue to provide targets from our pipeline to the market via more traditional partner licensing models, we felt the time was right to also establish our own therapeutic pipeline and have found exactly the collaborator we need in Myrio."

Pete Smith agreed, "With the close alignment of both scientific and business objectives between our two companies, a partnership between Myrio and Pure MHC just makes so much sense. We are excited about its potential."

The companies expect the collaboration to yield therapeutic candidates within the next twelve months.

About Myrio Therapeutics

Myrio Therapeutics is driving a new frontier of antibody-based therapies as the company's Retained Display(tm) (ReD) antibody platform offers identification of highly specific human antibodies that bind to peptide-MHC complexes. Myrio's antibodies can readily be converted into multispecific, CAR-T or other formats, dramatically increasing the target landscape for these modalities. Visit: http://www.myriotx.com/

About Pure MHC

Pure MHC, LLC is a platform technology company funded and managed by Emergent Technologies, Inc. with expertise in disease-specific target identification and validation as well as immunotherapeutic drug development for cancer, infectious disease, and autoimmune diseases. The Pure MHC target discovery technology was developed by Chief Scientist William Hildebrand, Ph.D., of the University of Oklahoma Health Science Center. For more information, visit: https://puremhc.com/

About Emergent Technologies

Emergent Technologies, Inc. is an innovation solutions and technology commercialization leader headquartered in Austin, Texas. Visit: http://www.etibio.com/

Pure MHC, LLC and Myrio Therapeutics Pty Ltd (Myrio) today announced a collaboration to develop new antibody-based oncology therapeutics. The companies will combine Pure MHC's proprietary offering of MHC peptide targets for oncology with Myrio's revolutionary Retained Display(tm) (ReD) antibody discovery process to initially create up to three novel therapies based on targets distinct to tumors across multiple types of cancer.

Related link: https://puremhc.com/